a50263137.htm

0001157523-12-002604.txt : 20120507 0001157523-12-002604.hdr.sgml : 20120507 20120507165549 ACCESSION NUMBER: 0001157523-12-002604 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120507 DATE AS OF CHANGE: 20120507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANIKA THERAPEUTICS INC CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 12818501 BUSINESS ADDRESS: STREET 1: 236 WEST CUMMINGS PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 6179326616 MAIL ADDRESS: STREET 1: 236 WEST CUMMINGS PARK CITY: WOBURN STATE: MA ZIP: 01801 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 10-Q 1 a50263137.htm ANIKA THERAPEUTICS, INC. 10-Q a50263137.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-21326

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Massachusetts	04-3145961
(State or Other Jurisdiction of	(I.R.S. Employer Identification No.)
Incorporation or Organization)

32 Wiggins Avenue, Bedford, Massachusetts	01730
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 457-9000

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report: N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer x	Non-accelerated filer o	Smaller reporting
		(Do not check if a smaller reporting company)	company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o No x

As of May 3, 2012, there were 13,763,861 outstanding shares of Common Stock, par value $.01 per share.

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(unaudited)

	March 31,			December 31,
	2012			2011
ASSETS
Current assets:
Cash and cash equivalents	$	34,003,178		$	35,777,222
Accounts receivable, net of reserves of $344,520 and $334,473 at March 31, 2012 and December 31, 2011, respectively		17,002,797			17,307,786
Inventories		9,080,323			7,302,483
Current portion deferred income taxes		1,918,926			1,918,926
Prepaid expenses and other		1,947,394			1,831,127
Total current assets		63,952,618			64,137,544
Property and equipment, at cost		51,541,804			50,850,630
Less: accumulated depreciation		(14,868,205	)		(14,380,752	)
		36,673,599			36,469,878
Long-term deposits and other		151,744			205,042
Intangible assets, net		23,300,273			23,148,563
Goodwill		9,150,273			8,883,407
Total Assets	$	133,228,507		$	132,844,434

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,880,840		$	4,299,680
Accrued expenses		4,297,387			5,321,594
Deferred revenue		2,866,667			2,866,667
Current portion of long-term debt		1,600,000			1,600,000
Income taxes payable		235,326			450,482
Total current liabilities		12,880,220			14,538,423
Other long-term liabilities		1,556,399			1,548,652
Long-term deferred revenue		4,302,773			5,019,440
Deferred tax liability		7,028,515			7,375,141
Long-term debt		9,200,000			9,600,000
Commitments and contingencies (Note 10)		-			-
Stockholders’ equity:
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively		-			-
Common stock, $.01 par value; 30,000,000 shares authorized, 13,763,191 and 13,630,607 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively		137,631			136,305
Additional paid-in-capital		64,269,349			63,441,433
Accumulated currency translation adjustment		(2,310,720	)		(3,067,181	)
Retained earnings		36,164,340			34,252,221
Total stockholders’ equity		98,260,600			94,762,778
Total Liabilities and Stockholders’ Equity	$	133,228,507		$	132,844,434

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income
(unaudited)

	Three Months Ended March 31,
	2012			2011
Product revenue	$	13,613,328		$	11,060,159
Licensing, milestone and contract revenue		747,332			677,520
Total revenue		14,360,660			11,737,679

Operating expenses:
Cost of product revenue		6,413,481			5,604,562
Research & development		1,533,103			1,532,664
Selling, general & administrative		3,351,016			4,043,774
Total operating expenses		11,297,600			11,181,000
Income from operations		3,063,060			556,679
Interest income (expense), net		(51,203	)		(40,921	)
Income before income taxes		3,011,857			515,758
Provision for income taxes		1,099,738			191,346
Net income	$	1,912,119		$	324,412

Basic net income per share:
Net income	$	0.15		$	0.03
Basic weighted average common shares outstanding		13,162,824			12,688,819
Diluted net income per share:
Net income	$	0.14		$	0.02
Diluted weighted average common shares outstanding		14,089,946			13,744,710

Net income		1,912,119			324,412
Other comprehensive income
Foreign currency translation adjustment		756,461			1,749,662
Comprehensive income	$	2,668,580		$	2,074,074

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(unaudited)
	Three Months Ended March 31,
	2012			2011
Cash flows from operating activities:
Net income	$	1,912,119		$	324,412
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization		986,913			920,410
Stock-based compensation expense		320,510			300,275
Deferred income taxes		(82,206	)		(111,293	)
Provision for inventory		49,558			711,533
Tax benefit from exercise of stock options		(394,076	)		-
Changes in operating assets and liabilities:
Accounts receivable		358,471			2,753,690
Inventories		(1,769,606	)		(374,014	)
Prepaid expenses, other current and long-term assets		(324,152	)		(580,852	)
Long-term deposits and other		8,499			8,499
Accounts payable		(476,940	)		(1,021,405	)
Accrued expenses		(1,341,407	)		(966,151	)
Deferred revenue		(716,667	)		(668,190	)
Income taxes payable		(215,156	)		2,198
Other long-term liabilities		(5,509	)		(13,165	)
Net cash (used in) provided by operating activities		(1,689,649	)		1,285,947

Cash flows from investing activities:
Purchase of property and equipment, net		(224,059	)		(76,570	)
Net cash used in investing activities		(224,059	)		(76,570	)

Cash flows from financing activities:
Principal payments on debt		(400,000	)		(400,000	)
Proceeds from exercise of stock options		114,656			28,945
Tax benefit from exercise of stock options		394,076			-
Net cash provided by (used in) financing activities		108,732			(371,055	)

Exchange rate impact on cash		30,932			38,556

(Decrease) increase in cash and cash equivalents		(1,774,044	)		876,878
Cash and cash equivalents at beginning of period		35,777,222			28,201,932
Cash and cash equivalents at end of period	$	34,003,178		$	29,078,810

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ANIKA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Business

Anika Therapeutics, Inc. (together with its subsidiaries, “Anika,” the “Company,” “we,” “us,” or “our”) develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (“HA”), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.

The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with the U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements as well as the ability to grow the Company’s business.

2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“U.S.”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. The year-end consolidated balance sheet is derived from our audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial position of the Company as of March 31, 2012 and the results of its operations for the three months ended March 31, 2012 and 2011 and cash flows for the three months ended March 31, 2012 and 2011.

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2011. There have been no changes in our significant accounting policies for the three months ended March 31, 2012 as compared to the significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the results to be expected for the year ending December 31, 2012. Certain prior period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.

3. Recent Accounting Pronouncements Issued or Adopted

On May 12, 2011, the Financial Accounting Standards Board (“FASB”), together with the International Accounting Standards Board, jointly issued Accounting Standards Update (“ASU”) 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. The provisions of ASU 2011-04 give fair value the same meaning between U.S. GAAP and International Financial Reporting Standards, and improve consistency of disclosures relating to fair value. For public entities, the amendments are effective during interim and annual periods beginning after December 15, 2011. The adoption of this amendment did not have a material impact on our consolidated financial position, results of operations, or cash flows.

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The amendments in this ASU require all non-owner changes in stockholders’ equity to be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this amendment did not have a material impact on our consolidated financial position, results of operations, or cash flows.

In September 2011, the FASB issued ASU 2011-08, Intangibles – Goodwill and Other. This ASU's objective is to simplify the process of performing impairment testing for Goodwill. With this update, a company is allowed to first assess qualitative factors to determine if it is more likely than not (greater than 50%) that the fair value of its goodwill and intangible assets is less than the carrying amount. This step is done prior to performing the two-step goodwill impairment testing, as prescribed by Topic 350. This ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. The adoption of this amendment did not have a material impact on our consolidated financial position, results of operations or cash flows.

4. Fair Value Measurements

We measure certain assets and liabilities, such as fixed income investments, at fair value based upon exit price, representing the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. To increase the comparability of fair value measurements, the following hierarchical levels of inputs to valuation methodologies are used:

•

Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 instruments include securities traded on active exchange markets, such as the New York Stock Exchange.

•

Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market.

•

Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect our own estimates of assumptions market participants would use in pricing the asset or liability.

The following table summarizes our assets measured and recorded at fair value on a recurring basis, by level, within the fair value hierarchy:

	March 31, 2012
	Level 1		Level 2		Level 3		Total
Cash equivalents - money market accounts	$	20,263,766	$	-	$	-	$	20,263,766

	December 31, 2011
	Level 1		Level 2		Level 3		Total
Cash equivalents - money market accounts	$	20,263,766	$	-	$	-	$	20,263,766

5. Equity Incentive Plan

The Company estimates the fair value of stock options and stock appreciation rights using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. The fair value of each stock option award during the three months ended March 31, 2012 and 2011 was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

	Three Months Ended March 31,
	2012	2011
Risk free interest rate	0.64%	1.51%
Expected volatility	57.60%	57.60%
Expected lives (years)	4	4
Expected dividend yield	0.00%	0.00%

The Company recorded $320,510 and $300,275 of share-based compensation expense for the three months ended March 31, 2012 and 2011, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to the respective employees.

There were 119,000 stock options granted under the Second Amended and Restated 2003 Stock Option and Incentive Plan (the “Second Amended 2003 Plan”) during the three months ended March 31, 2012. There were 16,480 restricted stock units (“RSUs”) granted to members of the Company’s Board of Directors under the Second Amended 2003 Plan during the same period ended March 31, 2012. The stock options and RSUs granted to employees and directors become exercisable or vest ratably over four years from the date of grant.

As of March 31, 2012, there was approximately $2.8 million of total unrecognized compensation cost related to non-vested stock options, stock appreciation rights (“SARs”), and restricted stock awards (“RSAs”) granted under the Company’s incentive plans. This cost is expected to be recognized over a weighted-average period of 2.6 years.

The total intrinsic value of stock options and SARs exercised during the three month periods ended March 31, 2012 and 2011 was approximately $1,192,545 and $13,875, respectively. Cash received from the exercise of stock options during the three-month periods ended March 31, 2012 and 2011 was $114,656 and $28,945, respectively.

There were approximately 2.0 million options and SARs outstanding under the Company’s incentive plans at March 31, 2012 with a weighted-average exercise price of $7.71 per share, an aggregate intrinsic value of approximately $9.9 million, and a weighted-average remaining contractual term of 6.78 years.

None of the options or SARs outstanding at March 31, 2012 or 2011, respectively, had cash-settlement features.

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either authorized but unissued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. Awards contain service or performance conditions and generally become exercisable ratably over one to four years and have a ten year contractual term.

6. Earnings Per Share

The Company reports earnings per share in accordance with Accounting Standards Codification (“ASC”) 260, Earnings Per Share, which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding and the number of dilutive potential common share equivalents during the period. Under the treasury stock method, unexercised “in-the-money” stock options are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period.

Basic and diluted earnings per share for the three months ended March 31, 2012 and 2011 are as follows:

	Three months ended March 31,
	2012		2011
Shares used in the calculation of Basic earnings per share		13,162,824		12,688,819
Effect of dilutive securities:
Stock options, SARs, RSAs, and shares held in escrow		927,122		1,055,891
Diluted shares used in the calculation of earnings per share		14,089,946		13,744,710

In connection with the acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”) on December 30, 2009, the Company issued 1,981,192 shares of its common stock of which 500,000 of these shares remain in escrow at March 31, 2012. These 500,000 shares are included in the diluted potential common shares but are excluded from the basic earnings per share calculation. See Note 10 for additional information relative to this item.

Equity awards of 380,551 and 979,438 shares were outstanding for the three months ended March 31, 2012 and 2011, respectively, but were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive.

7. Inventories

Inventories consist of the following:

	March 31,		December 31,
	2012		2011
Raw materials	$	5,035,600	$	4,091,366
Work-in-process		2,000,603		1,503,565
Finished goods		2,044,120		1,707,552
Total	$	9,080,323	$	7,302,483

Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead.

8. Intangible Assets and Goodwill

In connection with the acquisition of Anika S.r.l., the Company acquired various intangible assets and goodwill. The Company evaluated the various intangibles and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangibles. The in-process research and development intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition including write-off(s) for abandoned projects. Until such determination is made, they are not amortized.

The Company reviews its long-lived assets for impairment at least annually. Additionally, the Company will initiate a review for impairment if events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of the assets are no longer appropriate. Each impairment test will be based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Intangible assets as of March 31, 2012 and December 31, 2011 consist of the following:

			March 31, 2012								December 31, 2011
	Gross Value		Currency Translation Adjustment			Accumulated Amortization			Net Book Value		Net Book Value		Useful Life
Developed technology	$	16,700,000	$	(1,158,450	)	$	(2,275,506	)	$	13,266,044	$	13,228,351	15
In-process research & development		6,698,000		(464,629	)		-			6,233,371		5,955,066	Indefinite
Distributor relationships		4,700,000		(326,031	)		(1,968,286	)		2,405,683		2,547,842	5
Patents		1,000,000		(69,368	)		(130,870	)		799,762		790,555	16
Elevess trade name		1,000,000		-			(404,587	)		595,413		626,749	9
Total	$	30,098,000	$	(2,018,478	)	$	(4,779,249	)	$	23,300,273	$	23,148,563

The aggregate amortization expense related to intangible assets was $516,278 and $537,040 for the three months ended March 31, 2012 and 2011, respectively.

Changes in the carrying value of goodwill for the three months ended March 31, 2012 were as follows:

Balance at December 31, 2011	$	8,883,407
Effect of foreign currency adjustments		266,866
Balance at March 31, 2012	$	9,150,273

9. Accrued Expenses

Accrued expenses consist of the following:

	March 31,		December 31,
	2012		2011
Payroll and benefits	$	1,783,448	$	2,366,412
Professional fees		483,488		793,430
Research grants		1,019,284		989,556
Other		1,011,167		1,172,196
Total	$	4,297,387	$	5,321,594

10. Commitments and Contingencies

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any patent or intellectual property rights, trade secret or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligence or acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure. Based on the Company’s historical activity in combination with its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no accrued warranties and has no history of claims paid.

On July 7, 2010, Genzyme Corporation (“Genzyme”) filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable relief. The Complaint alleges that the Company has infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC in the United States for sale outside the United States and will infringe U.S. Patent Nos. 5,143,724 and 5,399,351 if the Company begins manufacture and sale of MONOVISC in the United States. On August 30, 2010, the Company filed an answer denying liability. On April 26, 2011, Genzyme filed a motion to add its newly-issued U.S. Patent No. 7,931,030 to this litigation and also filed a separate new complaint in the District of Massachusetts alleging that the Company's manufacture and sale of MONOVISC in the United States will infringe that patent. On May 23, 2011, the Court entered orders permitting Genzyme to file its supplemental complaint adding its newly-issued U.S. Patent No. 7,931,030 to this litigation and requiring Genzyme to withdraw its separately filed complaint. On July 14, 2011, the Company filed an answer to the supplemental complaint, denying liability. The Company believes that neither MONOVISC, nor its manufacture, does or will infringe any valid and enforceable claim of the asserted patents. Management has assessed and determined that contingent losses related to this matter are not probable. Therefore, pursuant to ASC 450, Contingencies, an accrual has not been recorded for this loss contingency. Pursuant to the terms of the licensing and supply agreement entered into with Depuy Mitek, Inc. in December 2011, DePuy Mitek agreed to assume certain obligations of the Company related to this litigaton.

In 2011, Merogel Injectable was withdrawn from the market due to a labeling error on the product’s packaging. We are working with Medtronic to resolve a dispute related thereto. Medtronic has informed us that if we are unable to resolve this dispute, they will make claims against us. As this labeling error relates to conduct that initially occurred prior to our acquisition of Anika S.r.l. from Fidia Farmaceutici S.p.A., we have made claims against Fidia for indemnification for Anika’s losses as well as any potential claims that may be brought by Medtronic. Fidia has informed us that it does not believe that it has liability for this matter, and has made claims against us for refusing to release the Anika shares that were put into escrow in connection with the original transaction. Management has assessed and determined that contingent losses related to this matter are not probable. Therefore, pursuant to ASC 450, Contingencies, an accrual has not been recorded for this loss contingency.

We are also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, we do not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position, results of operations or cash flow.

11. Long-term Debt

On January 31, 2008, the Company entered into an unsecured Credit Agreement with Bank of America. As of March 31, 2012, the Company had an outstanding debt balance of $10,800,000, at an interest rate of 1.72%. The interest payable on our debt is determined, at the Company’s option, based on LIBOR plus 1.25%, or the lender’s prime rate.

ASC 825, Financial Instruments, requires disclosure about the fair value of financial instruments in interim as well as in annual financial statements. The carrying value of our debt instrument was $10,800,000 and $11,200,000 at March 31, 2012 and December 31, 2011, respectively, of which $1,600,000 was recorded as current at each date. The estimated fair value of our debt, which is a Level 2 instrument for fair value measurement purposes, approximated book value at March 31, 2012 and December 31, 2011, respectively.

12. Income Taxes

Income tax expense was $1,099,738 and $191,346 for the three months ended March 31, 2012 and 2011, respectively. The effective tax rates were 36.5% and 37.1% for the three months ended March 31, 2012 and 2011, respectively.

In the normal course of business, Anika and its subsidiaries may be periodically examined by various taxing authorities. We file income tax returns in the U.S. federal jurisdiction, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. The 2008 through 2011 tax years remain subject to examination by the IRS and other taxing authorities for U.S. federal and state purposes. The 2009 through 2011 tax years remain subject to examination by the appropriate governmental authorities in Italy.

In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward, research and development (“R&D”) tax credit carryforward, and its investment tax credit carryforward. We have concluded that the positive evidence outweighs the negative evidence and, thus, that those deferred tax assets not otherwise subject to a valuation allowance are realizable on a “more likely than not” basis. As such, we have not recorded a valuation allowance at March 31, 2012 or December 31, 2011, respectively.

13. Related Party

In connection with our acquisition of Anika S.r.l. on December 30, 2009, Fidia Farmaceutici S.p.A. (“Fidia”) acquired ownership of 1,981,192 shares of the Company's common stock, of which 500,000 shares remain in escrow at March 31, 2012. As of March 31, 2012, Fidia owns approximately 14.4% of the outstanding shares of the Company.

As part of the acquisition, the Company, primarily through Anika S.r.l., entered into a series of operating agreements with Fidia as follows:

Agreement Type	Description	Term in Years
Lease	Rent of space in Abano Terme, Italy	Six
Finished goods supply	Manufacture and supply of goods	Three
Raw material supply	Hyaluronic acid powder	Five
Services	Finance, administrative, security	One to Six
Accounts receivable	Collection of trade receivables outstanding as of	Two
management	December 30, 2009.

Historically, Anika S.r.l. has relied on Fidia, its former parent company, for several functional activities. In connection with the purchase of Anika S.r.l., the Company has negotiated a lease for approximately 26,000 square feet of office, laboratory and warehouse space in Abano Terme, Italy, and a finished goods supply agreement. At March 31, 2012, Anika S.r.l. had a payable due to Fidia for past products and services of approximately $1.0 million.

14. Segment and Geographic Information

The Company has one reportable operating segment, the results of which are disclosed in the accompanying unaudited condensed consolidated financial statements.

Product revenue by product group is as follows:

	Three Months Ended March 31,
	2012		2011
Orthobiologics	$	10,116,845	$	8,036,298
Dermal		501,315		589,153
Ophthalmic		1,323,994		897,808
Surgical		983,628		1,113,728
Veterinary		687,546		423,172
	$	13,613,328	$	11,060,159

Product revenue by geographic location in total and as a percentage of total product revenue, for the three months ended March 31, 2012 and 2011 are as follows:

	Three Months Ended March 31,
	2012					2011
			Percentage of					Percentage of
Geographic Location:	Revenue		Revenue			Revenue		Revenue
United States	$	10,390,045		76	%	$	8,343,114		76	%
Europe		2,155,729		16	%		2,033,198		18	%
Other		1,067,554		8	%		683,847		6	%
Total	$	13,613,328		100	%	$	11,060,159		100	%

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding:

●	Our future sales and product revenue, including geographic expansions, possible retroactive price adjustments, and expectations of unit volumes or other offsets to price reductions;

●	Our manufacturing capacity and efficiency gains and work-in-process manufacturing operations;

●	The timing, scope and rate of patient enrollment for clinical trials;

●	The development of possible new products;

●	Our ability to achieve or maintain compliance with laws and regulations;

●	The timing of and/or receipt of the Food and Drug Administration, foreign or other regulatory approvals, clearances, and/or reimbursement approvals of current, new or potential products, and any limitations on such approvals;

●	Our intention to seek patent protection for our products and processes, and protect our intellectual property;

●	Our ability to effectively compete against current and future competitors;

●	Negotiations with potential and existing partners, including our performance under any of our existing and future distribution or supply agreements or our expectations with respect to sales and sales threshold milestones pursuant to such agreements;

●	The level of our revenue or sales in particular geographic areas and/or for particular products, and the market share for any of our products;

●	Our current strategy, including our corporate objectives and research and development and collaboration opportunities;

●	Our and Bausch & Lomb’s performance under the non-exclusive supply agreement for AMVISC® and AMVISC® Plus ophthalmic viscoelastic products, and our expectations regarding revenue generated from ophthalmic products;

●	Our ability to commercialize AnikaVisc and AnikaVisc Plus, and our expectations regarding such commercialization and the potential revenue generated thereby;

●	Our expectations regarding our joint health products, including expectations regarding new products, expanded uses of existing products, new distribution and revenue growth;

●	Our intention to increase market share for joint health products in international and domestic markets or otherwise penetrate growing markets for osteoarthritis of the knee and other joints;

●	Our expectations regarding next generation osteoarthritis/joint health product developments, clinical trials, regulatory approvals and commercial launches;

●	Our expectations regarding revenue from sales of HYVISC®;

●	Our ability to identify a new distribution partner for HYDRELLE™ in the United States and the impact this may have on future sales of this product;

●

Our ability to license our aesthetics product to new distribution partners outside of the United States; our ability, and the ability of our distribution partners, to market our aesthetic dermatology product; and our expectations regarding the distribution and sales of our ELEVESSTM product and the timing thereof;

●	Our expectations regarding our existing aesthetics product line’s extensions;

●	Our expectations regarding product gross margin;

●

Our expectations regarding our U.S. MONOVISC® trials and the results of the related premarket approval (“PMA”) filing with the FDA, including the escalation of the appeal process with the FDA as we actively seek an objective review of the scientific and clinical data, and the likelihood of our obtaining such approval and/or the anticipated timing thereof;

●	Our expectations regarding the commencement of a clinical trial for CINGAL™, including the expense associated therewith, and our ability to obtain regulatory approvals for CINGAL;

●	Our expectation for changes in operating expenses, including research and development and selling, general and administrative expenses;

●	The rate at which we use cash, the amounts used and generated by operations, and our expectation regarding the adequacy of such cash;

●	Our expectation for capital expenditures spending and future amounts of interest income and expense;

●	Possible negotiations or re-negotiations with existing or new distribution or collaboration partners;

●

Our expectations regarding the transfer of manufacturing and shipping of Anika products from our Woburn, MA manufacturing facility to our Bedford, MA facility (the “Bedford Facility”); and our ability to complete FDA licensure for the facility; and our expectation regarding the impact of the Bedford Facility on our business and the amount of the annual depreciation expense associated therewith;

●	Our ability to remain in compliance with debt covenants;

●	Our ability to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and other sources, to the extent our current sources of funds are insufficient;

●	Our abilities to successfully manage Anika Therapeutics S.r.l.’s (“Anika S.r.l.”), operations from one with losses, into a company generating profits;

●	Our abilities to effectively prioritize the many research and development projects underway;

●	Our ability to obtain U.S. approval for the orthopedic and other product franchises of Anika S.r.l., including the timing and potential success of such efforts, and to expand sales of these products in the U.S., including the impact such efforts may have on our revenue;

●	Our ability to satisfactorily resolve the potential dispute with Medtronic Xomed and Fidia Farmaceutici S.p.A; and

●	Our ability to successfully defend the Company against lawsuits and claims, including the Genzyme lawsuit, and the uncertain financial impact such lawsuits and claims and related defense costs may have on the Company.

Furthermore, additional statements identified by words such as “will,” “likely,” “may,” “believe,” “expect,” “anticipate,” “intend,” “seek,” “designed,” “develop,” “would,” “future,” “can,” “could,” and other expressions that are predictions of or indicate future events and trends and which do not relate to historical matters, also identify forward-looking statements.

You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control, including those factors described in the section titled “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. These risks, uncertainties and other factors may cause our actual results, performance or achievement to be materially different from anticipated future results, performance or achievement, expressed or implied by the forward-looking statements. These forward-looking statements are based upon the current assumptions of our management and are only expectations of future results. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences, including those factors discussed herein and in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of this Quarterly Report on Form 10-Q, as well as the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2011 and in our press releases and other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors of new information, future events or other changes.

Management Overview

In October 2011, we received additional orders from Bausch & Lomb (“B&L”) for ophthalmic products to be delivered in the first half of 2012. Effective January 1, 2012, the parties agreed to a new three year contract for Anika to continue to supply these products to B&L as a second supplier with additional committed volumes for 2012, and reduced annual commitments in 2013 and 2014. Currently we can only produce this product in our Woburn facility, and we expect to continue to occupy our Woburn facility until June 2012 in order to satisfy these commitments. During the first quarter of 2012, we received all FDA approvals required to manufacture our aseptic products in our Bedford facility, except for AmVisc and AmVisc Plus. We are currently working with B&L to obtain FDA approval for these products to be manufactured in our Bedford Facility, and expect to receive approval by the third quarter of 2012.

Anika S.r.l., our Italian subsidiary, has over 20 products currently commercialized, primarily in Europe. These products are all made from HA, and are based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by an extensive portfolio of patents. With the 2009 acquisition of Anika S.r.l., the Company is offering therapeutic products in the following areas:

	Anika	Anika S.r.l.
Orthobiologics	X	X
Dermal Advanced wound care Aesthetic dermatology	X	X
Ophthalmic	X
Surgical Anti-adhesion Ear, nose and throat care (“ENT”)	X	X X
Veterinary	X

During the first quarter of 2012, the Company entered into an agreement with a new distributor for Anika S.r.l.’s products in the Italian market, which consist of orthopedic and advanced wound care products. The transition to a new distributor resulted in a decline in Italian revenue during the first quarter of 2012 compared to the prior year. A significant portion of the Company’s accounts receivable arising from product sales within Italy by Anika S.r.l. are due from public hospitals and other government-funded healthcare agencies. As of March 31, 2012, the Company’s accounts receivable from all Italian customers totaled approximately $3.2 million of which public hospital and agency receivables were approximately $2.4 million.

Please see Management’s Discussion and Analysis of Financial Condition and Results of Operations-Management Overview (Item 7) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, for a description of each of the above therapeutic areas, including the individual products.

Research and Development

Anika’s research and development efforts primarily consist of the development of new medical applications for our HA-based technologies, the management of clinical trials and studies for certain product candidates, the preparation and processing of applications for regulatory approvals or clearances at all relevant stages of product development, and process development and scale-up manufacturing activities relative to our existing and new products. Our development focus includes products for new indications, chemically modified formulations of HA designed for longer residence time in the body, and other development activities. Our investment in R&D has been important over the years, and varies considerably depending on the number and size of clinical trials and studies underway. We anticipate that we will continue to commit significant resources to research and development, including clinical trials, in the future.

With the acquisition of Anika S.r.l., we have enhanced both our research and development capabilities and our pipeline of candidate products. Anika S.r.l. has research and development programs for new products including Hyalobone, a bone tissue filler; Hyalospine, an adhesion prevention gel for use after spinal surgery; and Hyalograft C Autograft (“HCA”) for cartilage regeneration. The Company currently plans to commence a multi-country, multi-year clinical trial for HCA in September 2012.

Hyalograft C Autograft is classified as an advanced therapy medicinal product under the current European Union regulations, which require a centralized marketing authorization by the European Medicines Agency. Our first next generation osteoarthritis product is MONOVISC, a single-injection treatment product that uses a non-animal source HA. MONOVISC is also our first osteoarthritis product based on our proprietary cross-linked HA-technology. We received Conformité Européenne (“CE”) Mark approval for the MONOVISC product in October 2007, and began sales in Europe during the second quarter of 2008, following a small, post-marketing clinical study. In the U.S., we filed the final module of our MONOVISC PMA containing the clinical data in December 2009. We were informed that there were deficiencies in our submissions through a deficiency/non-approvable letter, which is the FDA's mechanism for informing companies of deficiencies. We submitted additional data and analyses throughout 2010, and have been informed by the FDA that deficiencies remain. Acting on an option presented by the FDA to resolve the remaining open issues, Anika requested a review by the Orthopedic Advisory Panel. The FDA has denied our request for an Orthopedic Advisory Panel review of the product, and we are now moving to the next level in the appeal process structure of the FDA with a meeting for an objective review of the scientific and clinical data pending. We continue to believe in MONOVISC and the strength of our data, and that MONOVISC should receive FDA approval. Our second single-injection osteoarthritis product under development is CINGAL, which is based on our hyaluronic acid material with an added active therapeutic molecule to provide broad pain relief for a longer period of time. We filed a CE Mark application in the European Union for CINGAL in November 2011.

Contracts

As disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, Anika has been a contract manufacturer for B&L for over 20 years. Anika’s Supply Agreement with B&L expired on December 31, 2010. Effective January 1, 2011, we entered into a non-exclusive, two year contract with B&L intended to transition the manufacture of AMVISC and AMVISC Plus to an alternative, formerly affiliated low-cost supplier to B&L. Effective January 1, 2012, the parties agreed to a new three year contract for Anika to continue to supply these products to B&L as a second supplier with committed annual volumes in 2012, and a lower committed volume for 2013 and 2014. B&L accounted for approximately 16%, or $9.8 million, of our product revenue for the year ended December 31, 2011, but is expected to be moderately lower in 2012 under the new contract.

Litigation and Other Legal Matters

Results of Operations

Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(unaudited)

	Three Months Ended March 31,
	2012			2011			Inc/(Dec)			Inc/(Dec)
Product revenue	$	13,613,328		$	11,060,159		$	2,553,169			23	%
Licensing, milestone and contract revenue		747,332			677,520			69,812			10	%
Total revenue		14,360,660			11,737,679			2,622,981			22	%

Operating expenses:
Cost of product revenue		6,413,481			5,604,562			808,919			14	%
Research & development		1,533,103			1,532,664			439		NM
Selling, general & administrative		3,351,016			4,043,774			(692,758	)		-17	%
Total operating expenses		11,297,600			11,181,000			116,600			1	%
Income from operations		3,063,060			556,679			2,506,381			450	%
Interest income (expense), net		(51,203	)		(40,921	)		(10,282	)		25	%
Income before income taxes		3,011,857			515,758			2,496,099			484	%
Provision for income taxes		1,099,738			191,346			908,392			475	%
Net income	$	1,912,119		$	324,412		$	1,587,707			489	%
Product gross margin		7,199,847			5,455,597			1,744,250			32	%
Product gross margin		53	%		49	%

Product Revenue

Product revenue for the quarter ended March 31, 2012 was $13,613,328, an increase of 23%, compared to $11,060,159 for the quarter ended March 31, 2011. The first quarter increase was primarily driven by another strong quarter for our orthobiologics franchise, as well as strong performances for the quarter in our ophthalmic and veterinary franchises. Product revenue for the first quarter of 2011 was adversely impacted by an equipment problem at the Company’s Woburn, MA facility that caused $1.4 million of product scheduled to be shipped in late March 2011 to be delayed into the second quarter of 2011. Aproximately $1,167,000 of the delay was ophthalmic products, with the balance of the decline in joint health products. The problem also resulted in the loss of in-process product, further reducing gross margins for the quarter ended March 31, 2011.

The following table presents product revenue by group for the three month periods ended March 31, 2012 and 2011:

	Three Months Ended March 31,				Increase (Decrease)
	2012		2011		$			%
Orthobiologics	$	10,116,845	$	8,036,298	$	2,080,547		26	%
Dermal		501,315		589,153		(87,838	)	-15	%
Ophthalmic		1,323,994		897,808		426,186		47	%
Surgical		983,628		1,113,728		(130,100	)	-12	%
Veterinary		687,546		423,172		264,374		62	%
	$	13,613,328	$	11,060,159	$	2,553,169		23	%

Orthobiologics

The orthobiologics group consists of our joint health and orthopedic products. Overall, sales increased 26% for the three months ended March 31, 2012, as compared to the same period in 2011. The increases were led by our joint health products ORTHOVISC and MONOVISC, the latter of which is currently only available outside the U.S. Revenue from joint health products increased 29% during the three months ended March 31, 2012, as compared to the same periods in 2011. Our U.S. joint health product revenue for the three months ended March 31, 2012 increased 27% as compared to the same period in 2011. This increase reflects DePuy Mitek’s continued market penetration efforts in the U.S. for ORTHOVISC. The improvement in international joint health product revenue was primarily due to increased sales in Europe.

International orthobiologics product revenue increased 23%, as compared to the same period in 2011, led by ORTHOVISC and MONOVISC, and despite a decrease in Anika S.r.l.’s orthopedic sales due to weakness in certain European economies, and reduced sales in Italy during our transition to a new distributor. We expect joint health product revenue to increase in 2012 as compared to 2011, both domestically and internationally.

Dermal

Our dermal products consist of advanced wound care products and aesthetic dermal fillers. Overall, dermal product sales decreased 15% for the quarter to $501,315, primarily due to lower sales in Italy and the U.S. for its advanced wound care products. Anika’s advanced wound care products treat skin wounds ranging from burns to diabetic ulcers. Leading products include Hyalograft 3D, Hyalofill and Hyalomatrix. Aesthetic dermatology revenue was $201,698 for the three months ended March 31, 2012, as compared to $15,228 for the same period in 2011, primarily due to sales to our Korean distributor. The aesthetics’ market is crowded with many products, and our sales expectations in this area are modest for 2012.

Ophthalmic

Our ophthalmic business consists of HA viscoelastic products used in ophthalmic surgery. Ophthalmic product sales increased 47% to $1,323,994 for the three months ended March 31, 2012, as compared to the same period in 2011. The increase during the first quarter was primarily attributable to increased sales to B&L. As previously disclosed, we expect ophthalmic revenue to be slightly lower in 2012 compared to 2011 as B&L continues its transition to a formerly affiliated alternative supplier.

Surgical

Our surgical group consists of products used to prevent post-surgical adhesions in abdominal, spinal, and ear, nose and throat (“ENT”) disorders. Sales of our surgical products decreased 12% to $983,628 for the three months ended March 31, 2012, as compared to the same period in 2011, primarily due to order timing in the ENT area. Our anti-adhesion products include Hyalobarrier and INCERT. Hyalobarrier had increased sales in both Europe and Korea compared to the same period last year. Sales of our ENT product sold through our worldwide partner, Medtronic, decreased 57% for the three month ended March 31, 2012, as compared to the same period in the prior year, primarily due to order timing, which we expect to recover in future quarters.

Veterinary

Veterinary revenue from HYVISC increased 62% to $687,546 for the three months ended March 31, 2012. The increase for the three month period was primarily due to order timing by our distribution partner, Boehringer Ingelheim Vetmedica. We expect overall HYVISC revenue for 2012 to be at a comparable level to 2011’s revenue for this product.

Licensing, milestone and contract revenue

Licensing, milestone and contract revenue for the three months ended March 31, 2012 was $747,332 as compared to $677,520 during the same period in 2011. Licensing and milestone revenue includes the ratable recognition of the $27,000,000 in up-front and milestone payments related to the U.S. distribution agreement with Depuy Mitek received in 2004. These amounts are being recognized in income over the ten-year expected life of the agreement, or $2,700,000 per year. In December 2011, the Company also entered into a fifteen-year licensing and supply agreement with DePuy Mitek to market MONOVISC in the U.S. The Company received an initial payment of $2,500,000 in December 2011, which will be recognized ratably over the fifteen year term of the agreement.

Product gross profit and margin

Product gross profit for the three months ended March 31, 2012 and 2011 was $7,199,847 and $5,455,597, or 53% and 49% of product revenue, respectively. The increase in product gross profit and margin for the quarter as compared to the same quarter in the previous year was primarily due to a more favorable product mix, as well as the impact of an equipment problem in late March 2011 at the Company’s Woburn facility that resulted in a loss of a batch of in-process product. In connection with the equipment problem, the Company wrote-down its inventory by approximately $450,000 in the first quarter of 2011.

The Company plans to transfer a significant portion of the Anika S.r.l. product manufacturing to its location in Bedford, MA over the next two years, starting with the ACP gel products in the second half of 2012. This is expected to have a favorable impact on gross margin. Looking forward, we expect gross margin in the U.S. to remain under pressure from government healthcare cost control initiatives. During the first quarter of 2012, we received all FDA approvals required to manufacture our aseptic products in our Bedford Facility, except for AmVisc and AmVisc Plus. We are currently working with B&L to obtain FDA approval for these products, and expect to receive approval by the third quarter of 2012. Commencing with these FDA approvals to manufacture U.S. products in our Bedford Facility, we expect annual depreciation expense to increase approximately $1.5 million.

Research and development

Research and development expenses for the three months ended March 31, 2012 and 2011 were $1,533,103 and $1,532,664, respectively, or 11% and 13% of total revenue, and reflect a relatively low level of clinical study spending. Spending is expected to increase in future quarters with increased expenditures planned on clinical trials for Hyalograft C and CINGAL, as well as spending on further development of Anika’s pipeline of new products and new products expected to be developed based on our technology assets.

Selling, general and administrative

Selling, general and administrative (“SG&A”) expenses for the three months ended March 31, 2012 and 2011 were $3,351,016 and $4,043,774, respectively, or 23% and 34% of total revenue. This represents a decrease of 17% for the quarter as compared to the same quarter in the prior year. The decrease in expense for the quarter was primarily due to placing in service the remainder of the Bedford manufacturing facility. Prior to this quarter, the previously unoccupied space was expensed to SG&A. We expect general and administrative expenses to show decreases in 2012 compared to the prior year’s quarter, and grow modestly in future years.

Interest income (expense), net

Net interest expense was $51,203 and $40,921 for the three months ended March 31, 2012 and 2011, respectively. The increase in interest expense for the quarter is due to a higher interest rate in 2012 as compared to 2011.

Income taxes

Provisions for income taxes were $1,099,738 and $191,346 for the three months ended March 31, 2012 and 2011, respectively, based on effective tax rates of 36.5 % and 37.1 %, respectively. The decrease in the effective tax rate for 2012 compared to 2011 is due to the improved results for 2012 expected at our Italian subsidiary as compared to the prior year.

The Company files income tax returns in the U.S. on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. Our 2008 through 2011 tax years remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. The 2009 through 2011 tax years remain subject to examination by the appropriate governmental authorities for Italy.

In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward, R&D tax credit carryforward, and its investment tax credit carryforward. We have concluded that the positive evidence outweighs the negative evidence and, thus, that those deferred tax assets not otherwise subject to a valuation allowance are realizable on a “more likely than not” basis. As such, we have not recorded a valuation allowance at March 31, 2012 or December 31, 2011, respectively.

Liquidity and Capital Resources

We require cash to fund our operating expenses and capital expenditures. We expect that our requirements for cash to fund operations will increase as the scope of our operations expands. Historically, we funded our cash requirements from operations, available cash and investments on hand, and debt. Cash and cash equivalents totaled approximately $34.0 million and $35.8 million at March 31, 2012 and December 31, 2011, respectively. Working capital totaled approximately $51.1 million at March 31, 2012 and $49.6 million at December 31, 2011, respectively. The Company believes it has adequate financial resources to support its business for the foreseeable future.

Cash used by operating activities was $1,689,649 for the three months ended March 31, 2012 as compared to cash provided by operating activites of $1,285,947 for the same period in the prior year. This decrease in cash provided by operations was due primarily to an increase in net working capital requirements as compared to the same period in 2011 related to higher accounts receivable, due to the timing of sales during the quarter, plus a build-up in our inventories related to the Woburn facility closure.

Cash used in investing activities was $224,059 for the three months ended March 31, 2012 as compared to $76,570 for the same period in 2011. The increase is due to planned capital projects associated with maintaining our Bedford facility. We expect overall capital spending during 2012 to be higher than in 2011 due to the completion of the capital maintenance projects combined with the planned transfer of manufacturing activities for certain Anika S.r.l. products from Italy to our Bedford facility.

Cash provided by financing activities was $108,732 for the three months ended March 31, 2012 as compared to cash used by financing activities of $371,055 for the same period ended 2011. The increase in cash provided is attributable to an increase in funds due to employee stock option exercises, combined with their associated income tax benefits received during the first three months of 2012 as compared to the same period in the prior year.

Critical Accounting Estimates

There have been no significant changes in our critical accounting estimates during the three months ended March 31, 2012, as compared to the critical accounting estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Recent Accounting Pronouncements

Information with respect to Recent Accounting Pronouncements may be found in Note 3 of the Notes to Condensed Consolidated Financial Statements (unaudited) in this Form 10-Q, which information is incorporated herein by reference.

Contractual Obligations and Other Commercial Commitments

We have made significant capital investments related to the build-out and validation of our facility in Bedford, Massachusetts. This capital project has been financed with cash on hand and the proceeds of a $16,000,000 unsecured Credit Agreement with Bank of America entered into on January 31, 2008. This term loan has quarterly principal payments of $400,000 and a final installment of $5,200,000 due on the maturity date of December 31, 2015. We commenced making quarterly principal payments on March 31, 2009. Total debt outstanding was $10,800,000 as of March 31, 2012. Interest is payable at a rate based upon (at the Company’s election) either Bank of America’s prime rate or LIBOR plus 125 basis points.

To the extent that funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and others, or through other sources. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our market risks since the date of our Annual Report on Form 10-K for the year ended December 31, 2011.

As of March 31, 2012, we did not utilize any derivative financial instruments, market risk sensitive instruments or other financial and commodity instruments for which fair value disclosure would be required under ASC 825, Financial Instruments, and ASC 815, Derivatives and Hedging. Our investments consist of money market funds primarily invested in U.S. Treasury obligations and repurchase agreements secured by U.S. Treasury obligations, and municipal bonds that are carried on our books at amortized cost, which approximates fair market value.

Primary Market Risk Exposures

Our primary market risk exposures are in the areas of interest rate risk and currency rate risk. We have three supplier contracts denominated in foreign currencies. Unfavorable fluctuations in exchange rates would have a negative impact on our financial statements. The impact of changes in currency exchange rates for these supplier contracts on our financial statements was immaterial for the three months ended March 31, 2012. The impact of exchange rates related to the consolidation of the balance sheet amounts for our Anika S.r.l. subsidiary resulted in a favorable currency translation adjustment of $756,461 during the first three months of 2012.

Our investment portfolio of cash equivalents and long-term debt are subject to interest rate fluctuations. As of March 31, 2012, we were subject to interest rate risk on $10.8 million of variable rate debt. The interest payable on our debt is determined, at the Company's option, based on LIBOR plus 1.25% or the lender’s prime rate and, therefore, is affected by changes in market interest rates. Based on the outstanding debt amount as of March 31, 2012, we would have a decrease in future annual cash flow of approximately $100,000 for every 1% increase in the interest rate over the next twelve month period.

ITEM 4. CONTROLS AND PROCEDURES

(a)

Evaluation of disclosure controls and procedures.

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the chief executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and our internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

(b)

Changes in internal controls over financial reporting.

There were no changes in our internal control over financial reporting during the first three months of fiscal year 2012 that have materially affected, or that are reasonably likely to materially affect, our internal controls over financial reporting.

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

To our knowledge, there have been no material changes to the risk factors described in “Part I., Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011, except to the extent additional factual information disclosed elsewhere in this Quarterly Report on Form 10-Q relates to such risk factors. In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 6. EXHIBITS

Exhibit No.		Description

(31)		Rule 13a-14(a)/15d-14(a) Certifications

*31.1		Certification of Charles H. Sherwood, Ph.D. pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*31.2		Certification of Kevin W. Quinlan pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

(32)		Section 1350 Certifications

**32.1		Certification of Charles H. Sherwood, Ph.D. and Kevin W. Quinlan, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(101)		XBRL

101§		The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, as filed with the SEC on May 4, 2012, formatted in XBRL (eXtensible Business Reporting Language), as follows:

		i. Condensed Consolidated Balance Sheets as of March 31, 2012 (unaudited) and December 31, 2011 ii. Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2012 and March 31, 2011 (Unaudited) iii. Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2012 and March 31, 2011 (Unaudited) iv. Notes to Condensed Consolidated Financial Statements (Unaudited)

*	Filed herewith
**	Furnished herewith.
§	As provided in Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933, as amended, and Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ANIKA THERAPEUTICS, INC.

May 4, 2012	By:	/s/ KEVIN W. QUINLAN
		Kevin W. Quinlan
		Chief Financial Officer
		(Authorized Officer and Principal Financial Officer)

EX-31.1 2 a50263137ex31_1.htm EXHIBIT 31.1 a50263137ex31_1.htm

Exhibit 31.1

CERTIFICATION

I, Charles H. Sherwood, certify that:

1.	I have reviewed this report on Form 10-Q for the quarterly period ended March 31, 2012 of Anika Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2012	/s/ CHARLES H. SHERWOOD
	Charles H. Sherwood, Ph. D.
	Chief Executive Officer
	Principal Executive Officer

EX-31.2 3 a50263137ex31_2.htm EXHIBIT 31.2 a50263137ex31_2.htm

Exhibit 31.2

CERTIFICATION

I, Kevin W. Quinlan, certify that:

1.	I have reviewed this report on Form 10-Q for the quarterly period ended March 31, 2012 of Anika Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2012	/s/ KEVIN W. QUINLAN
	Kevin W. Quinlan
	Chief Financial Officer
	Principal Financial Officer

EX-32.1 4 a50263137ex32_1.htm EXHIBIT 32.1 a50263137ex32_1.htm

Exhibit 32.1

Section 906 Certification

The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2012	/s/ CHARLES H. SHERWOOD
	Charles H. Sherwood, Ph.D.
	Chief Executive Officer
	Principal Executive Officer


Date: May 4, 2012	/s/ KEVIN W. QUINLAN
	Kevin W. Quinlan
	Chief Financial Officer
	Principal Financial Officer

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Exchange Act.

EX-101.INS 5 anik-20120331.xml XBRL INSTANCE DOCUMENT 13763861

29078810

1918926

12880220

2866667

9200000

36164340

4297387

1947394

17002797

133228507

4302773

235326

137631

9080323

13763191

1250000

63952618

9150273

1556399

34003178

0.01

64269349

344520

7028515

51541804

14868205

133228507

98260600

13763191

0.01

36673599

1600000

30000000

3880840

-2310720

23300273

151744

28201932

1918926

14538423

2866667

9600000

34252221

5321594

1831127

17307786

132844434

5019440

450482

136305

7302483

13630607

1250000

64137544

8883407

1548652

35777222

0.01

63441433

334473

7375141

50850630

14380752

132844434

94762778

13630607

0.01

36469878

1600000

30000000

4299680

-3067181

23148563

205042

28945

-13165

-76570

-2753690

5604562

1749662

11181000

1285947

2074074

515758

300275

0.02

-966151

-111293

400000

324412

1532664

2198

920410

-40921

711533

76570

0.03

11737679

556679

-1021405

11060159

677520

4043774

191346

876878

12688819

580852

38556

374014

-668190

13744710

-371055

-8499

Q1 ANIK ANIKA THERAPEUTICS INC false Accelerated Filer 2012 10-Q 2012-03-31 0000898437 --12-31

114656

-5509

-224059

-358471

6413481

756461

<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 14.          Segment and Geographic Information</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has one reportable operating segment, the results of which are disclosed in the accompanying unaudited condensed consolidated financial statements.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product revenue by product group is as follows:</font></div> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">  </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="68%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="30%" colspan="6"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Three Months Ended March 31,</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="68%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2012</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="14%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2011</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="68%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Orthobiologics</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,116,845</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,036,298</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="68%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dermal</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">501,315</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">589,153</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="68%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ophthalmic</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,323,994</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">897,808</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="68%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Surgical</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">983,628</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,113,728</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="68%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Veterinary</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">687,546</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">423,172</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="68%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,613,328</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,060,159</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> </table> </div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br />  </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product revenue by geographic location in total and as a percentage of total product revenue, for the three months ended March 31, 2012 and 2011 are as follows:</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="92%"> <tr> <td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="46%" colspan="14"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Three Months Ended March 31,</font></div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2012</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2011</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr> <td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Percentage of</font></div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Percentage of</font></div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Geographic Location:</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Revenue</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Revenue</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Revenue</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Revenue</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="52%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">United States</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,390,045</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,343,114</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="52%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Europe</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,155,729</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,033,198</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> </tr> <tr bgcolor="#CCEEFF"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,067,554</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">683,847</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="52%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,613,328</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,060,159</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td> </tr> </table> </div> </div> </div>

<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 11.          Long-term Debt</font></div> <div> </div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 31, 2008, the Company entered into an unsecured Credit Agreement with Bank of America. As of March 31, 2012, the Company had an outstanding debt balance of $10,800,000, at an interest rate of 1.72%. The interest payable on our debt is determined, at the Company’s option, based on LIBOR plus 1.25%, or the lender’s prime rate.  </font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ASC 825, <font style="FONT-STYLE: italic; DISPLAY: inline">Financial Instruments</font>, requires disclosure about the fair value of financial instruments in interim as well as in annual financial statements. The carrying value of our debt instrument was $10,800,000 and $11,200,000 at March 31, 2012 and December 31, 2011, respectively, of which $1,600,000 was recorded as current at each date. The estimated fair value of our debt, which is a Level 2 instrument for fair value measurement purposes, approximated book value at March 31, 2012 and December 31, 2011, respectively.</font></div> </div>

11297600

-1689649

2668580

<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 6.             Earnings Per Share</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company reports earnings per share in accordance with Accounting Standards Codification (“ASC”) 260, <font style="FONT-STYLE: italic; DISPLAY: inline">Earnings Per Share</font>, which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding and the number of dilutive potential common share equivalents during the period. Under the treasury stock method, unexercised “in-the-money” stock options are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted earnings per share for the three months ended March 31, 2012 and 2011 are as follows: </font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="92%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="26%" colspan="6"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Three months ended March 31,</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2012</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2011</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares used in the calculation of Basic earnings per share</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,162,824</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,688,819</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effect of dilutive securities:</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options, SARs, RSAs, and shares held in escrow</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">927,122</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,055,891</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Diluted shares used in the calculation of earnings per share</font></div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,089,946</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,744,710</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> </table> </div> <br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with the acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”) on December 30, 2009, the Company issued 1,981,192 shares of its common stock of which 500,000 of these shares remain in escrow at March 31, 2012. These 500,000 shares are included in the diluted potential common shares but are excluded from the basic earnings per share calculation. See Note 10 for additional information relative to this item.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity awards of 380,551 and 979,438 shares were outstanding for the three months ended March 31, 2012 and 2011, respectively, but were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive.</font></div> </div>

3011857

320510

0.14

-1341407

-82206

400000

1912119

1533103

394076

-215156

986913

-51203

49558

224059

0.15

14360660

<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 8.             Intangible Assets and Goodwill</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with the acquisition of Anika S.r.l., the Company acquired various intangible assets and goodwill. The Company evaluated the various intangibles and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangibles. The in-process research and development intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition including write-off(s) for abandoned projects. Until such determination is made, they are not amortized. </font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company reviews its long-lived assets for impairment at least annually. Additionally, the Company will initiate a review for impairment if events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of the assets are no longer appropriate. Each impairment test will be based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.</font></div> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">  </div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intangible assets as of March 31, 2012 and December 31, 2011 consist of the following:</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="92%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="34%" colspan="10"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> March 31, 2012</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="22%" colspan="5"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> December 31, 2011</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Gross Value</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Currency</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Translation Adjustment</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Accumulated Amortization</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Net Book</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Value</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Net Book</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Value</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Useful Life</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Developed technology</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,700,000</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,158,450</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,275,506</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,266,044</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,228,351</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: center" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In-process research & development</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,698,000</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(464,629</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,233,371</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,955,066</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="10%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indefinite</font></div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Distributor relationships</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,700,000</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(326,031</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,968,286</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,405,683</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,547,842</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: center" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patents</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000,000</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(69,368</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(130,870</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">799,762</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">790,555</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: center" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Elevess trade name</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000,000</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(404,587</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">595,413</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">626,749</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,098,000</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,018,478</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,779,249</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,300,273</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,148,563</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> </table> </div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br />  </div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The aggregate amortization expense related to intangible assets was $516,278 and $537,040 for the three months ended March 31, 2012 and 2011, respectively.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in the carrying value of goodwill for the three months ended March 31, 2012 were as follows:</font></div> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">  </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="86%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2011</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,883,407</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="86%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effect of foreign currency adjustments</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">266,866</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="86%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at March 31, 2012</font></div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,150,273</font></td> </tr> </table> </div> </div> </div>

-394076

3063060

-476940

13613328

747332

3351016

1099738

-1774044

13162824

324152

30932

1769606

<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.             Accrued Expenses</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses consist of the following:</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="92%"> <tr> <td valign="bottom" width="72%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="12%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> March 31,</font></div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td valign="bottom" width="12%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> December 31,</font></div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2012</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 2011</font></div> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payroll and benefits</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,783,448</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,366,412</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Professional fees</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">483,488</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">793,430</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research grants</font></div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,019,284</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">  </font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">989,556</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,011,167</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,172,196</font></td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,297,387</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,321,594</font></td> </tr> </table> </div> </div> </div>

-716667

<div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 13.          Related Party</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with our acquisition of Anika S.r.l. on December 30, 2009, Fidia Farmaceutici S.p.A. (“Fidia”) acquired ownership of 1,981,192 shares of the Company's common stock, of which 500,000 shares remain in escrow at March 31, 2012. As of March 31, 2012, Fidia owns approximately 14.4% of the outstanding shares of the Company.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As part of the acquisition, the Company, primarily through Anika S.r.l., entered into a series of operating agreements with Fidia as follows:</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"> <div align="center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="92%"> <tr> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Agreement Type</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Description</font></div> </td> <td valign="top" width="14%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Term in Years</font></div> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Lease</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rent of space in Abano Terme, Italy</font></div> </td> <td valign="top" width="14%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Six</font></div> </td> </tr> <tr bgcolor="white"> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished goods supply</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture and supply of goods</font></div> </td> <td valign="top" width="14%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three</font></div> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Raw material supply</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Hyaluronic acid powder</font></div> </td> <td valign="top" width="14%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Five</font></div> </td> </tr> <tr bgcolor="white"> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Services</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finance, administrative, security</font></div> </td> <td valign="top" width="14%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">One to Six</font></div> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collection of trade receivables outstanding as of</font></div> </td> <td valign="top" width="14%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Two</font></div> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top" width="28%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> management</font></div> </td> <td valign="top" width="58%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> December 30, 2009.</font></div> </td> <td valign="top" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font></td> </tr> </table> </div> <br /></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Historically, Anika S.r.l. has relied on Fidia, its former parent company, for several functional activities. In connection with the purchase of Anika S.r.l., the Company has negotiated a lease for approximately 26,000 square feet of office, laboratory and warehouse space in Abano Terme, Italy, and a finished goods supply agreement. At March 31, 2012, Anika S.r.l. had a payable due to Fidia for past products and services of approximately $1.0 million.</font></div> </div>

14089946

108732

-8499

0000898437 2012-01-01 2012-03-31 0000898437 2011-01-01 2011-03-31 0000898437 2011-12-31 0000898437 2010-12-31 0000898437 2012-03-31 0000898437 2011-03-31 0000898437 2012-05-03 shares iso4217:USD iso4217:USD shares

EX-101.SCH 6 anik-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Business link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Recent Accounting Pronouncements Issued or Adopted link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Equity Incentive Plan link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Earnings Per Share link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Intangible Assets and Goodwill link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Long-term Debt link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Related Party link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Segment and Geographic Information link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 anik-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 anik-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 anik-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable And Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable Current Accounts payable Accounts Receivable Net Current Accounts receivable, net of reserves of $344,520 and $334,473 at March 31, 2012 and December 31, 2011, respectively Accrued Income Taxes Current Income taxes payable Accrued Liabilities Current Accrued expenses Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Less: accumulated depreciation Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax Accumulated currency translation adjustment Additional Paid In Capital Additional paid-in-capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net income to net cash (used in) provided by operating activities: Allowance For Doubtful Accounts Receivable Current Accounts receivable, reserves Amendment Flag Amendment Flag Assets Total Assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Business Description And Basis Of Presentation [Text Block] Basis of Presentation Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease (Decrease) increase in cash and cash equivalents Commitments And Contingencies Commitments and contingencies (Note 10) Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $.01 par value; 30,000,000 shares authorized, 13,763,191 and 13,630,607 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively Comprehensive Income Net Of Tax Comprehensive income Cost Of Goods Sold Cost of product revenue Costs And Expenses Total operating expenses Costs And Expenses [Abstract] Operating expenses: Current Fiscal Year End Date Current Fiscal Year End Date Deferred Income Tax Expense Benefit Deferred income taxes Deferred Revenue Current Deferred revenue Deferred Revenue Noncurrent Long-term deferred revenue Deferred Tax Assets Net Current Current portion deferred income taxes Deferred Tax Liabilities Noncurrent Deferred tax liability Noncurrent Deposits And Other Assets. Deposits And Other Assets Noncurrent Long-term deposits and other Depreciation Depletion And Amortization Depreciation and amortization Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Equity Incentive Plan Document - Document and Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share Basic Net income Earnings Per Share Basic [Abstract] Basic net income per share: Earnings Per Share Diluted Net income Earnings Per Share Diluted [Abstract] Diluted net income per share: Earnings Per Share [Text Block] Earnings Per Share Effect Of Exchange Rate On Cash And Cash Equivalents Exchange rate impact on cash Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Excess Tax Benefit From Share Based Compensation Financing Activities Tax benefit from exercise of stock options Fair Value Disclosures [Text Block] Fair Value Measurements Goodwill Goodwill Goodwill And Intangible Assets Disclosure [Text Block] Intangible Assets and Goodwill Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Income before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Tax Expense Benefit Provision for income taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Income Taxes Payable Income taxes payable Increase Decrease In Accrued Liabilities Accrued expenses Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Inventories Inventories Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Noncurrent Liabilities Other long-term liabilities Increase Decrease In Other Operating Assets Long-term deposits and other Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses, other current and long-term assets Intangible Assets Net Excluding Goodwill Intangible assets, net Interest Income Expense Nonoperating Net Interest income (expense), net Inventory Disclosure [Text Block] Inventories Inventory Net Inventories Inventory Write Down Provision for inventory Legal Entity [Axis] Legal Entity [Axis] Liabilities And Stockholders Equity Total Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Long Term Debt Current Current portion of long-term debt Long Term Debt Noncurrent Long-term debt Long Term Debt [Text Block] Long-term Debt Nature Of Operations Nature of Business Net Cash Provided By Used In Financing Activities Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided By Used In Investing Activities Net cash used in investing activities Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided By Used In Operating Activities Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities [Abstract] Cash flows from operating activities: Net Income Loss Net income Net income Notes to Financial Statements [Abstract] Notes To Financial Statements [Abstract] Notes to Financial Statements [Abstract] Operating Income Loss Income from operations Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease Foreign currency translation adjustment Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive income Other Liabilities Noncurrent Other long-term liabilities Payments To Acquire Property Plant And Equipment Purchase of property and equipment, net Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively Prepaid Expense And Other Assets Current Prepaid expenses and other Proceeds From Stock Options Exercised Proceeds from exercise of stock options Property Plant And Equipment Gross Property and equipment, at cost Property Plant And Equipment Net Property, Plant and Equipment, Net, Total Related Party Transactions Disclosure [Text Block] Related Party Repayments Of Long Term Debt Principal payments on debt Research And Development Expense Research & development Retained Earnings Accumulated Deficit Retained earnings Sales Revenue Goods Net Product revenue Sales Revenue Net Total revenue Sales Revenue Services Net Licensing, milestone and contract revenue Segment Reporting Disclosure [Text Block] Segment and Geographic Information Selling General And Administrative Expense Selling, general & administrative Share Based Compensation Stock-based compensation expense Significant Accounting Policies [Text Block] Recent Accounting Pronouncements Issued or Adopted Statement [Line Items] Statement [Line Items] Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Stockholders Equity Total stockholders' equity Stockholders Equity [Abstract] Stockholders' equity: Tax Benefit From Stock Options Exercised Tax benefit from exercise of stock options Trading Symbol Trading Symbol Weighted Average Number Of Diluted Shares Outstanding Diluted weighted average common shares outstanding Weighted Average Number Of Shares Outstanding Basic Basic weighted average common shares outstanding EX-101.PRE 10 anik-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2012

Fair Value Measurements

4. Fair Value Measurements

•

The following table summarizes our assets measured and recorded at fair value on a recurring basis, by level, within the fair value hierarchy:

	March 31, 2012
	Level 1		Level 2		Level 3		Total
Cash equivalents - money market accounts	$	20,263,766	$	-	$	-	$	20,263,766

	December 31, 2011
	Level 1		Level 2		Level 3		Total
Cash equivalents - money market accounts	$	20,263,766	$	-	$	-	$	20,263,766

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R9&0R,&-A,E\V-CDV7S0T8CE?.3-A95\S9#,V M-69C,&,R.60B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D5Q=6ET>5]);F-E;G1I=F5?4&QA;CPO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DEN=F5N=&]R:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I%>&-E;%=O'!E;G-E M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN8V]M95]487AE#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='D\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R M9&0R,&-A,E\V-CDV7S0T8CE?.3-A95\S9#,V-69C,&,R.60-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F1D,C!C83)?-C8Y-E\T-&(Y7SDS865? M,V0S-C5F8S!C,CED+U=O'0O:'1M;#L@8VAA2!);F9O2`P,RP@,C`Q,CQB'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^04Y)2SQS M<&%N/CPO'0^04Y)2T$@5$A%4D%0155424-3($E.0SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'10 M87)T7S)D9#(P8V$R7S8V.39?-#1B.5\Y,V%E7S-D,S8U9F,P8S(Y9`T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R9&0R,&-A,E\V-CDV7S0T8CE? M.3-A95\S9#,V-69C,&,R.60O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ+#DQ."PY,C8\2P@4&QA;G0@86YD($5Q=6EP;65N="P@3F5T+"!4;W1A;#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)FYB'0^)FYB M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9&0R,&-A,E\V-CDV M7S0T8CE?.3-A95\S9#,V-69C,&,R.60-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,F1D,C!C83)?-C8Y-E\T-&(Y7SDS865?,V0S-C5F8S!C,CED M+U=O'0O M:'1M;#L@8VAA'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'!E;G-E&5S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ+#`Y.2PW,S@\3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\R9&0R,&-A,E\V-CDV7S0T8CE?.3-A95\S9#,V-69C,&,R M.60-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F1D,C!C83)?-C8Y M-E\T-&(Y7SDS865?,V0S-C5F8S!C,CED+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XY.#8L.3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!B96YE9FET(&9R;VT@97AE'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT+"!N M970\+W1D/@T*("`@("`@("`\=&0@8VQA"!B96YE9FET(&9R;VT@ M97AE&-H86YG92!R871E M(&EM<&%C="!O;B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS,"PY,S(\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HQ+B8C>$$P.R8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.R8C>$$P.R8C>$$P.PT*3F%T=7)E(&]F($)U6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@$$P.TEN8RX@*'1O9V5T:&5R('=I=&@@:71S('-U8G-I9&EA#(P,4,[06YI:V$L)B-X,C`Q1#L@=&AE("8C>#(P,4,[0V]M<&%N>2PF M(W@R,#%$.R`F(W@R,#%#.W=E+"8C>#(P,40[#0HF(W@R,#%#.W5S+"8C>#(P M,40[(&]R("8C>#(P,4,[;W5R)B-X,C`Q1#LI(&1E=F5L;W!S+"!M86YU9F%C M='5R97,@86YD#0IC;VUM97)C:6%L:7IE#(P,40[*2P@82!N871U7,@86X@:6UP;W)T86YT(')O M;&4@:6X@82!N=6UB97(@;V8-"G!H>7-I;VQO9VEC86P@9G5N8W1I;VYS('-U M8V@@87,@=&AE('!R;W1E8W1I;VX@86YD(&QU8G)I8V%T:6]N(&]F#0IS;V9T M('1I2!I2!T96-H;F]L;V=Y+"!C;VUM M97)C:6%L:7IA=&EO;B!O9B!E>&ES=&EN9R!A;F0@;F5W#0IP2!T;R!G'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/&1I=CX- M"CQD:78@6EN M9R!U;F%U9&ET960@8V]N9&5N2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E#(P M,4,[52Y3+B8C>#(P,40[*2X@5&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN M8VQU9&4@=&AE(&%C8V]U;G1S#0IO9B!!;FEK82!4:&5R87!E=71I8W,L($EN M8RX@86YD(&ET28C>#(P,3D[ M$$P.S$P+4L@9F]R('1H92!Y96%R M(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3$N#0I4:&5R92!H879E(&)E M96X@;F\@8VAA;F=E$$P.S$P+4L@9F]R('1H92!F:7-C86P@>65A6QE/3-$)U1%6%0M24Y$14Y4.B`S-G!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE$$P.S,Q+"`R,#$R+B!# M97)T86EN('!R:6]R('!E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K)SX-"CQD:78@6QE/3-$)U1%6%0M24Y$14Y4.B`S-G!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE2`Q,BP@,C`Q,2P@=&AE($9I;F%N8VEA;"!! M8V-O=6YT:6YG(%-T86YD87)D#(P,4,[1D%30B8C>#(P M,40[*2P@=&]G971H97(@=VET:"!T:&4@26YT97)N871I;VYA;"!!8V-O=6YT M:6YG#0I3=&%N9&%R9',@0F]A#(P,4,[05-5)B-X,C`Q1#LI(#(P M,3$M,#0L(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E3 M4$Q!63H@:6YL:6YE)SY!;65N9&UE;G1S('1O($%C:&EE=F4@0V]M;6]N#0I& M86ER(%9A;'5E($UE87-U6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@6QE/3-$)T9/ M3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY#;VUP6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@#(P,3,[($=O;V1W:6QL#0IA;F0@3W1H97(\+V9O M;G0^+B!4:&ES($%352=S(&]B:F5C=&EV92!I2!T:&4@ M<')O8V5S6EN9R!A;6]U;G0N)B-X03`[5&AI2!4;W!I8R`S-3`N#0I4 M:&ES($%352!I7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/&1I=CX-"CQD:78@ M6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY790T*;65A2!O9B!F86ER('9A;'5E#0IM96%S=7)E;65N=',L M('1H92!F;VQL;W=I;F<@:&EE6QE/3-$)U=)1%1(.B`R-W!T)SX-"CQD:78^/&9O;G0@ M$$P.SPO9F]N=#X\+V1I M=CX-"CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U! M4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(W@R,#(R.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0^#0H\ M9&EV(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE&-H86YG M92X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T6QE/3-$)U=)1%1(.B`R-W!T)SX-"CQD:78^/&9O;G0@$$P.SPO9F]N=#X\+V1I=CX- M"CPO=&0^#0H\=&0@6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=) M3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(W@R,#(R.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0^#0H\9&EV M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE#(P,C([/"]F;VYT/CPO9&EV M/@T*/"]T9#X-"CQT9#X-"CQD:78@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,979E;`T*,R`F(W@R,#$S.R!686QU M871I;VX@:7,@9V5N97)A=&5D(&9R;VT@;6]D96PM8F%S960@=&5C:&YI<75E M6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@ M+SX\+V1I=CX-"CQD:78@3H\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B8C>$$P M.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:R<^#0H\9&EV(&%L:6=N/3-$8V5N=&5R/@T*/'1A8FQE('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^#0I-87)C:"`S,2P@,C`Q,CPO9F]N=#X\+V1I M=CX-"CPO=&0^#0H\=&0@$$P.SPO9F]N=#X\+W1D/@T*/"]T"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O M;G0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E' M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^#0I,979E;"`S/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@"<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1C96YT97(^/&9O;G0@6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY#87-H#0IE<75I=F%L96YT"<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/CPO=&0^#0H\=&0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`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`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@ M8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^#0I,979E;"`S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^ M/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY#87-H#0IE<75I=F%L96YT"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXM/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HU+B8C>$$P.R8C M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P M.R8C>$$P.R8C>$$P.R8C>$$P.PT*17%U:71Y($EN8V5N=&EV92!0;&%N/"]F M;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\ M+V1I=CX-"CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0S,24@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@ M=F%L:6=N/3-$=&]P('=I9'1H/3-$,34E/@T*/&1I=B!S='EL93TS1"=415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M#0HR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C8T M)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$,24^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$U)3X- M"CQD:78@6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$U)3X-"CQD:78@ M65A6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^ M/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C`P)3PO9F]N=#X\+V1I=CX-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$U)3X-"CQD:78@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I=CX-"CQD:78@6QE/3-$)U1%6%0M24Y$14Y4.B`S-G!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE65E6QE/3-$)U1% M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I=CX- M"CQD:78@F5D(&-O;7!E;G-A M=&EO;B!C;W-T(')E;&%T960@=&\@;F]N+79E6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I M=CX-"CQD:78@2`D,2PQ.3(L-30U(&%N9"`D,3,L.#6QE/3-$)U1%6%0M24Y$14Y4.B`S-G!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE2`R+C`@;6EL;&EO M;B!O<'1I;VYS(&%N9"!305)S(&]U='-T86YD:6YG('5N9&5R#0IT:&4@0V]M M<&%N>28C>#(P,3D[2`D.2XY(&UI;&QI;VXL(&%N9"!A#0IW96EG M:'1E9"UA=F5R86=E(')E;6%I;FEN9R!C;VYT2P@:&%D(&-A6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\ M+V1I=CX-"CQD:78@F5D(&)U="!U;FES&5R8VES92!P28C M>#(P,3D[2!B96-O;64@97AE2!O=F5R(&]N M92!T;R!F;W5R('EE87)S(&%N9`T*:&%V92!A('1E;B!Y96%R(&-O;G1R86-T M=6%L('1E3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9&0R,&-A,E\V-CDV7S0T8CE? M.3-A95\S9#,V-69C,&,R.60-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,F1D,C!C83)?-C8Y-E\T-&(Y7SDS865?,V0S-C5F8S!C,CED+U=O'0O:'1M;#L@ M8VAA6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T* M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`S M-G!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE#(P,40[*2`R-C`L M(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@ M:6YL:6YE)SY%87)N:6YG#(P,4,[:6XM M=&AE+6UO;F5Y)B-X,C`Q1#L@6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"87-I8PT*86YD(&1I;'5T960@96%R M;FEN9W,@<&5R('-H87)E(&9O6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I=CX-"CQD:78@"<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-S(E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,C8E(&-O;'-P86X],T0V/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I4:')E M92!M;VYT:',@96YD960@36%R8V@@,S$L/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T* M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^#0HR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3:&%R97,-"G5S960@ M:6X@=&AE(&-A;&-U;&%T:6]N(&]F($)A$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,BPV.#@L.#$Y/"]F M;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(@8F=C;VQO6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%9F9E8W0-"F]F(&1I M;'5T:79E('-E8W5R:71I97,Z/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3=&]C:PT* M;W!T:6]N"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`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`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXQ-"PP.#DL.30V/"]F;VYT/CPO=&0^#0H\=&0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`S M-G!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE#(P,4,[ M06YI:V$@4RYR+FPN)B-X,C`Q1#LI(&]N($1E8V5M8F5R(#,P+"`R,#`Y+"!T M:&4@0V]M<&%N>0T*:7-S=65D(#$L.3@Q+#$Y,B!S:&%R97,@;V8@:71S(&-O M;6UO;B!S=&]C:R!O9B!W:&EC:"`U,#`L,#`P(&]F#0IT:&5S92!S:&%R97,@ M6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I M=CX-"CQD:78@3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9&0R,&-A,E\V-CDV7S0T8CE? M.3-A95\S9#,V-69C,&,R.60-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,F1D,C!C83)?-C8Y-E\T-&(Y7SDS865?,V0S-C5F8S!C,CED+U=O'0O:'1M;#L@ M8VAA6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,B4@8V]L6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I$96-E;6)E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^#0HR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY287<-"FUA=&5R:6%L6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXU+#`S-2PV,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY7;W)K+6EN+7!R;V-E$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR M+#`P,"PV,#,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N M;W=R87`^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@ M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXQ+#4P,RPU-C4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO M6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`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`Q,'!T M)SXW+#,P,BPT.#,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O M;G0@$$P.SPO9F]N=#X\ M+W1D/@T*/"]T'1087)T7S)D9#(P8V$R M7S8V.39?-#1B.5\Y,V%E7S-D,S8U9F,P8S(Y9`T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B\R9&0R,&-A,E\V-CDV7S0T8CE?.3-A95\S9#,V-69C M,&,R.60O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"CQD:78@3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M24Y$14Y4.B`S M-G!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE0T*86-Q=6ER960@ M=F%R:6]U$$P.U1H92!I;BUPF5D+B8C>$$P.SPO9F]N=#X\ M+V1I=CX-"CQD:78@2!R979I97=S(&ET M2P@=&AE($-O;7!A;GD@=VEL;"!I;FET M:6%T92!A(')E=FEE=R!F;W(-"FEM<&%I2!R96-O=F5R86)L90T*;W(@=&AA="!T:&4@=7-E9G5L(&QI=F5S M(&]F('1H92!A6QE/3-$)U1%6%0M24Y$14Y4 M.B`S-G!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X] M,T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O M;G0@$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S0E(&-O;'-P86X] M,T0Q,#X-"CQD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@;F]W6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^#0I$96-E;6)E6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E' M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C@E M/@T*/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O M;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I'$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#=7)R M96YC>3PO9F]N=#X\+V1I=CX-"CQD:78@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^#0I!8V-U;75L871E9"!!;6]R=&EZ871I;VX\+V9O;G0^ M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@;F]W6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I686QU93PO9F]N M=#X\+V1I=CX-"CPO=&0^#0H\=&0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I5$$P M.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX-"B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX-"B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ M,RPR-C8L,#0T/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B0\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY);BUP6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`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`Q,'!T)SY);F1E9FEN:71E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X- M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,2PY-C@L,C@V M/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXR+#4T-RPX-#(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N M;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C M96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU/"]F;VYT/CPO=&0^#0H\=&0@ M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@ M8F=C;VQO6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY0871E;G1S/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#`P M,"PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R M87`^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L M:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`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`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=415A4+4%,24=..B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-CPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY%;&5V97-S#0IT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R M<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXM/"]F;VYT/CPO=&0^#0H\=&0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U! M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-#`T+#4X M-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@;F]W6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M$$P.SPO9F]N=#X\+W1D/@T*/"]T#L@4$%$1$E.1RU,1494.B`P<'0[($U!4D=)3BU,1494.B`Y M<'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(X)2!A;&EG;CTS1&QE9G0^ M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4 M;W1A;#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXH,BPP,3@L-#"<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,"4^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M)SX\8G(@+SX-"B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E. M1$5.5#H@,S9P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@'!E;G-E(')E;&%T960@=&\@:6YT86YG:6)L92!A6QE/3-$ M)U1%6%0M24Y$14Y4.B`S-G!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX- M"CQD:78@86QI9VX],T1C96YT97(^#0H\=&%B;&4@6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY"86QA;F-E#0IA="!$96-E;6)E$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%9F9E8W0-"F]F(&9O M6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U! M3$E'3CH@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C M;VQO XML 14 R8.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements Issued or Adopted

3 Months Ended

Mar. 31, 2012

Recent Accounting Pronouncements Issued or Adopted

3. Recent Accounting Pronouncements Issued or Adopted

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 15 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) (USD $)	Mar. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 34,003,178	$ 35,777,222
Accounts receivable, net of reserves of $344,520 and $334,473 at March 31, 2012 and December 31, 2011, respectively	17,002,797	17,307,786
Inventories	9,080,323	7,302,483
Current portion deferred income taxes	1,918,926	1,918,926
Prepaid expenses and other	1,947,394	1,831,127
Total current assets	63,952,618	64,137,544
Property and equipment, at cost	51,541,804	50,850,630
Less: accumulated depreciation	(14,868,205)	(14,380,752)
Property, Plant and Equipment, Net, Total	36,673,599	36,469,878
Long-term deposits and other	151,744	205,042
Intangible assets, net	23,300,273	23,148,563
Goodwill	9,150,273	8,883,407
Total Assets	133,228,507	132,844,434
Current liabilities:
Accounts payable	3,880,840	4,299,680
Accrued expenses	4,297,387	5,321,594
Deferred revenue	2,866,667	2,866,667
Current portion of long-term debt	1,600,000	1,600,000
Income taxes payable	235,326	450,482
Total current liabilities	12,880,220	14,538,423
Other long-term liabilities	1,556,399	1,548,652
Long-term deferred revenue	4,302,773	5,019,440
Deferred tax liability	7,028,515	7,375,141
Long-term debt	9,200,000	9,600,000
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively
Common stock, $.01 par value; 30,000,000 shares authorized, 13,763,191 and 13,630,607 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively	137,631	136,305
Additional paid-in-capital	64,269,349	63,441,433
Accumulated currency translation adjustment	(2,310,720)	(3,067,181)
Retained earnings	36,164,340	34,252,221
Total stockholders' equity	98,260,600	94,762,778
Total Liabilities and Stockholders' Equity	$ 133,228,507	$ 132,844,434

XML 16 R6.htm IDEA: XBRL DOCUMENT

Nature of Business

3 Months Ended

Mar. 31, 2012

Nature of Business

1. Nature of Business

XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2012

Basis of Presentation

2. Basis of Presentation

XML 19 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Mar. 31, 2012	Dec. 31, 2011
Accounts receivable, reserves	$ 344,520	$ 334,473
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,250,000	1,250,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	13,763,191	13,630,607
Common stock, shares outstanding	13,763,191	13,630,607

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 20 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2012

Income Taxes

12. Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

XML 21 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2012	May 03, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1
Trading Symbol	ANIK
Entity Registrant Name	ANIKA THERAPEUTICS INC
Entity Central Index Key	0000898437
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,763,861

ZIP 22 0001157523-12-002604-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-12-002604-xbrl.zip M4$L#!!0````(``*'IT`:('`>5DP``&9\`P`1`!P`86YI:RTR,#$R,#,S,2YX M;6Q55`D``^0VJ$_D-JA/=7@+``$$)0X```0Y`0``[%UI<^-&DOVN"/V'6LZ. M8S>"I'`#5+L]P1:E'NVTCI%DMSU?.D"@2-8T"'!P2*)__696`20`@@K'OSU./7)/PX@%_ON6W)5:A/I.X#)__+Z51!T[?$A^=:A'0[B3_&)T9;5KD4XG&^(F2'SWF"BYC_BH@(BX\`A]3;<#Y"_#NUH>3]^4+C_0>5WR[U>[XA?S6YE4:`ILKD)C+AC M,7;$JD:&6^6C7R\^W3H3.K4[90ELGQ4!X0=V/`$=SV@2,R?J.L'T"!4GJ:J< M/>:`JN-POGB2(XNHTQT']T?I17Q([DAR9_F82UGU(W"AXG;FW],HKGY"7*MX MR`]\/YE6Z\V-PZ-X/J-'<%,'[J(A`B!N"6]I2MK'(F+A5OCREMU<6O<`F,GA)N[=QQQH[BA(\)M M[Q@AO&]%;#KST$+X9W;HA(%'=[-R_L0DI*/W+32D3F8WWV8_]**)Q=$GC MDP0^\>/:6M\=NMR3K9YB+)%O@%'$^XG90^:QF-%H#S`5RY(4):?AU>FKU7E# M[ZF?T.8A*I8!_YFKFBPB*"DQ\,=W-)P.Z#"^#'RG<90]\'[X+Z?'2@1%E#N`\VT$RUIRU1[P!G1=>8PT0W MU*%`>T./[H?&3$E2S%Y1WVN!E"!S:9H$IZJ*8NE2'AV?1@F48\)0^HM]"0Q3A?AR$/8E(!",E2Y>%O23R!)X32YF_M)/`E"]CO4Y4TA5O1B M)-\,HXKSFO=90^WIBB%;9>:K]-2/0>`^,,]KTAED'0@OYPS9G$4D/,KE0O5> MN%C6=5!7;XEM/8KM]M>$RVSQV@:*L%IYH@9UK6Q:SRK"G01BSW_GG:X=NDMLUR[`422]DKR\">FU3!F[B MA#$)/)>&$3X0S_=;Y6Q#LSV,G4=1\H(IU.8(5@300+S://U>5ZMG*89DY-/' M;U''H]N????212G]G0U@FRE01$[BBI+IB)5QN*7 MPE]N]4`M-F:@O\6>RNFCXR58GNVAZE5452J6O;L`$B+@9B2DD;,@8KPKE&L` M[ZDJEDT-$L.=<#1?D0+X&CM"\$!/5=[(MJ!<`_HK;@O6@JGIJJ7EFYM[V1:L M`_'UM@7KH.QMBJ-[VQ:L@UC5%%U1E%R"]5K;@G50ZZHBZ_D-ME?;%JSE9I8* MMYN%7/;5M@5K`3=5R30M8S6=:6A;L!8X5;$T35.U@MMJ/G63V/;@G5`@6V+;B*8VT7 M`I;.R/>T7FE;<'?$K[4M6,?X#$U635U;8;Z7W!:L@\>R+%7+KW+#VX*UV$/7 M+$//$=SK;`NN-\#];PO6RA-UTS0A47QCVX(;17CCVX*U/%W5-%E3OJ]733$,Q\X=H]K,M^)()^=ZV!5\DAK_R MMF"M8&AH1L_*&\<^MP5KD=*V()"60ZD;G87!E/O:U0P7*SI] MI*'#HCH.WZO_JJ#5T_0"@6[&4C88)Z1V1`=4_'ONH;P&M6W(IS2G. MOA,C7,WPRROVQ@BR8NE0#&VEA`I8*XEE>6WK)S-/B#.2J<'_A=QR'8X5#LL2 M&PA*8K>0/E#(6K$2*(XB"L<+"MFL*TB4 M[R8URBVR;NI6@0CW)5:I?L=,_@.XH(M+`/H77ZO2H.C\L%>`>4G\PJG0QI(XQXEKL.P0:DM'*1H-M<#CLBYOB;0E0-4=X87)I83X@?IT M5.?PS%,2.$BV>Q7O_:[!4C[X,[/GW-2O1OG*NDG$6JE67H=A)9@L7;91GU,T M358*X6(Y<5E[$;5#!_>@!O2>>@'OF*3Z;C2FX?O3AI;7X08D.[I;CB_37D"C M84WN63NXW"JHLN=M;ZTW*49/D32Y<+QF.YZ5U@&/24+2=,F@W@JR?*16*["F M!+Q]U=&DGE+@O^V(UIQT^0Q1E@Z"AT9U;LI@_U7G71:SE]H$*;W[*J&>7"<4M&7'VF:/_]),)5%W]>UBM,;U,ID,:7HU6CI&]4"19C1R\"6-8EB7G'+06JFW*KT>FC,['],;VQ8WKE5YM!H_60!<$K%_5K MP-JV;%GBUG"!KYJ:)&N;5B<'9!OFTOGY1L.P88#+;-P"**'9R?'3)LPSCI'6 ME?G_Y\=WYR M2\XO3_)?EUN<:`FC#]IPN48\NXZW%NT,(4ZTSJ-VJ'SS,H_+G*I!8CKTY]-Y\]?87Q6G$^'&YU$F'2 MI[X[P.]R?XYT'4GMJ"6W*8Q>7MP3N`%2]W/?I8__H$]?7NSD6CT+ZH/"]ST7 M1U].GAXN6JK_N<+C]87DZT9O[M!(`,USHT M4E\<1=&D?/?@C9P:J2^(JEN0:[W.H9'::/'=,=7=\=$FL7OR.#\]OI3_[=C,L1)WY&+_LW'\\O.I].S[([TDYOS MCW\7'[6([8&6WK<\.HI;^YP'9QF!6K)I%H,R_A=:WI&SJ\N[SEG_XOP3?!BS M*?"73Q\(L+SMIU=OS_]U>DQD/B7_X/.IF!%23S>51I:Z/]C3V;N_//:E=R_] MT^%!SA`(U%JD8`HHXQ$*F0E\5%C,H_+2\MN6TU3=4KDJJO%&EX4/>>X?'C@T MQ.^C(,&(L+06"\$;HS8!]R7HOK8_)P]VB"E[1.)`W`:>":X<1H<'\<2.^;VS M,'`3>!)N(#!E,H)AP-?XF*,@G.*SN?L.#Z(9T,>(.>)<"['A29]0WH(AZ9@H M!D)SJ0?\`:DZ_)P;HWMX<)=#.;7GH+8HR."2[=C12B=;3)/0OP M+#4)0C($?G$F!(>>P4S&P8JDNNX'/'L?$/+157(5L(#BR=M?L'Q;#;%&_D/$8).-9,:3:IN!!*$AP=\5J$?>`CFIF,8 MSZ5\8=/)T@4ACIU$XH]"@:"P%'0,9@\^RO6/=LAU.&51Q&TD7?Y4(3G^R)G! MX<$4I$>C!FF7*^^E:1HJ#F(`OAU)9H''G+DP$X]-69QJDC[.>)SH$GX>B M42;@:WX`>/DQA/SZ@;4<'J27A63O\&5(TN)V_EA61`799&'C829"$0+;`.?RNQ>>PJA=V M!)G7!#PP!F.)*/V*S)#X*3&CT]I3,,[4+"B>(^19?HCF.5K:5(J->WJT9-V< MN1T>9`SKDI^[MUUR+0CU,N@2O2UK:MM4-*2!)3LCEHNKRZM?SF]/N$>M"HE" M138``C:+H)BIT`/2'[X/L@10FC_*`\"[];;:Z[55729L5/;*,9)*+H#P!P2" M41[L*A"D]<.#?C(&DB:JE!E&7DWI/+J(UCZ07D!,H:J8KH6YP"$+Y.2"PZB#$=T8)A''@?\P0%PJ-A=1\$R! M%%>.NQ@$-^;RU:>8)CE4=!5$!B+<$:P*4BX01ZPR>-:%[0-+\3-.G&KPCBBB M8AR7QKBT/OS*;,187YQ@"@82 M8:0&RQ.1.0:]4Q]P.VB\+A'F_7YQYK5^Y;*5F$;%S0,QM0#T_DWU!:<*A[`0S+6],D( MAN'&,+7#KU"0N0FG54BI/!NY"VR5AB&6&'Z^3BQF^#/;^6ICZ,J1(/E,D1_` MCH.09TW!SQR28#Y6&0&V_YY(37P5@B M@LTF:38%F<@#GQ"R,RXFND`V`7?]=`Y.^W/!K%/[*\TR]RQO3*+OB-O M%)4AAK4G1$V'=[_=Y6"0E00\L$!XA58(G(MN%\)-PBN4&YO&> M+AJNT+`XHY`B@3@/!IW$G'"AB'3"X`'Y-2WQ%W4I/@X%+!@X:B->MF/+@97L M&%?!N2H#*ZD35WF(R0(K>9-Q]=6+X.?3]-,#T4Y,_1D($E>;5Q#,OT>ZP@2` MW-O`%F#2HCL&A8'HI>%V(9ZZ7G2I1,:/+3K@"4R\P3IX33!,_X1XGLV\>()N M*PPZB7&O(5KT28"RULZ%312T0#^&A,5E(Z"4Q..9W0PH#JH9SDE9JY`^SJ@C M"ES.P$G&<'#-IO,?BM^DR7ED[MC?/"&SO#=#W_\5C97 MOLVM$JW!K1*2+B4V;ETH/H-Q:,\FD(F<+QO5=?=+WI3>O^?,,1;MBWX+CW:! MC_2%SLOSR<7K3R02UM#.""ZE'?(`)C$1=.X*7Q=4SDMRQQ%#B_ZAG;@L?2O7 MQ9/`_"=@2N:*]'=)'A.4X!UY&<]-)WO"SNEV:D\5[O"^0NZ:,.A\HKBSDHD# M)4($]1[8,9YIX+_/1)./__[`W'CROF7J?\U/&.9^=K.9K_N#P?GEQ\Z'J[N[ MJXMCHLP>6[AWPT$/@S@.IHOQ#"L_W@M;S29FB]WG0I>;0;X^%M87Y\/5S>#T M9B'-T(-Z'F4BG)+62J9*?P4#"-`>X**QC\0B9\O[4N?=)*247,!,DXB<^ECV M7.#+UD25V]NB_E/4G3)+CFLVF18490^0C;QOB7_WJIE=#>VHX/_?N>!;Y`)9 MRW.!\HUR`=9@WWW^NW]\]X^U_B%_]X\GQ$0R'(-Q!.'[UE].3DY/S\Y:!25M MB(3?R"E8<2PHC"?!D($BQLS9>@2U9$@;["&]PD\@-H6]/I/4,>G&\IW#@_]^ M"EZARK6`U081RU);EHVVI>E-*+IY[JAK+=_M^L]AUU9;4HVVTK/^!&:]-OH] M3%A,_Y2Q;T!Q`^][S-L+-SP/^"N2A"[);57^'OF^6_RG@")+$CL4J>9A6_/K][U7 MQ4N'=5BR):H:2-N6R*I75>^N=[0:9X#=ROQ;9OY-Q_'8\B:NK<2@8A1/VH!: MPVQHO5[S#%B%PN_SP^]NKZ-U=64)GJ48O$W"$6;+*B&HF,13H/>Z#:UMG@.3 M4-A]?MAM:(:!*SSSOPD M%[49>SK`LMK=CM9JME_CH(Z,=2F:4C2UGV4US89F=):$UYT=36UC$Z\@ON;I MQL\^!?J)\0U8"G."9.#QHV`<&T=$;+685V,88!ZTX5]CS_9O=D:TT3,!8?-4><-[YR3.2DK`&ZVBPDG M1O,E7'Z5R,ZLBLAZ?J)ERSQJ0_$\$\E,\QR2KL\ET5*1@B(%E5.Y7TFGU,L] MPU8J\V$>`:"GKZE5R-!8AA[5X\(W15]$%0R+@Z*$XF:*FRENIKC9"7&S`_A. M*A)QMWIO"Z50/TDW_CI?NC)HGRH2=!;,1W:K/P>;=I\XI4A$D8@B$44BBD04 MB2@2422B2.3X"C)6R.JC(44CR7I-=)+<$I%.+N3T2%(V#U"XKG?8>HR-GJ[I MJAZC0NO7RD0^)'YW-D[S.T*\_D6AL^+2.&A7:S0;FF&HBDD*JQ63/BZ\7L.D M]U`BJ6IVR8U4#95_FZJIDO7^(Q#[>T7G:[OSU29J*J M;&W"B`[!AC2]W=%:K8W=@*=U#;SCR2FB4D3U'-]ZA8EIO:&F:$C1T#XJJC:T M;K-384I28DF1U,N25(6):8]79BN(K3E]_)6E'RY:C.*3WG3U9AS$:.V]GM%Z MA^77]F.TJHJ4AUK5:U2D/*"UJBJ\*GJJ@F9P=(2EZU6FJ)V-5D5(2C"I2LE* M,!T_/2G!=(H4M8W9NDW)\?2OO_TEB2Y&EC7]ZRT?3;@??^73((Q=?W3E1K87 M1$G([_AC_`Y-R]_J-<;^EK[P*?!'=SR<7/%!G#W";``5_OC*A__]$P^\[S0;C]D[ MR__!@B'K3WCHVE;A-/L1?EZN`4^3U6OI;&/+P4F")(YBR\OJN@:8KC$KAL?K-9>`C&(66C$]9%QVS%\*4]_!BK*'IM:,"JX' M.%$H)G"C>LW!)G83V%*'!B[L@AP(`.[]"HN88F$=#8"*8!M@E$_7P/O8U$M@ M$./2;/VB,5D#W\.Z]V'Y]6D(1T20+L?TM3BY-=VFS0RJ@K[]V_?U6M=L:6Q^ M?3:BSD?R8N8`QS M,E[-K`'@)AWMT')#%&"):(8P3$>$:;(!L8<"H9T[P?8&#]SS\"=\:OE`?1X; MYG!$F-)+;\WAK6V%X0PI(9VL@+795.S!`N0KT`9U;?@9]&(S_3N>(SUZXHK; M?#+@(7XJ2MOBNJ,IMV/WGGLS#>=[&+OPWL^&UI9CP63PE!V$6-X=?@>&$"(0 M%K`#;L&S#F(W0^B!X-P)_.64-RQ;@R9'=['!Q"<. M!'TU3<)I$/$(R'4Z#8-'.=$@"'[4:^+Q]:NF!A0:=L/(5WVYSJVZ(-Z72NNR M0'\?1''4]YT/CU,.3#3:598#"W;%2VX4-.&5[]]NKWZ"S;1A_5Z$71]^,PRS MUX'3R@&O[>B\4T8W+MPIN]FWX"U7?M?IASX%.!>'S?&C=W#0GUA MM+N]=K.70[TY7/-[/9F&?`PKA?.\]NU@PF&H+\,[Z_&0"S#;[6ZK6]KUE7"4 M`?Y@A3ZL)[KAX>W8*BB%KZ+Q[Q%E$&) M`A,8S31!\$G<`0N*.*TF6WZ]EJW_$E3VR+67[DPD1T*I.@,]"+@PCN+S&&4T MLC-FW5NN1_HT&`CPR03VAMX>`R'Q,,(745]ZX.C"0'WA'ICW"([&3T@&@S)0 M?"TJ:_])B#]P``#+#9Q+=N5Z"15!V0Y@M@3>>FT+@-D*>.NU(L"XW_AV_K"# M\`+[9],@QE,`M:_X/JP#U$S05DAA7++>;VA"B(Y:(2D_,SALE`P3'H\#![`A M\?DC#VT7S9$B5KK^!;QV`5/Q61$]Y?O"CHED\ZT(U"V']F0`6ELVGC2$!GSD M^KC;N*(<.K1S++2>H@2)1V,NJ,(>:&&AT/[284$[LSEWQ%SP.MB1$3ZSP!YPAV$Y`HHN;=`"C:7-F=$?,Z#,PHZ^[^0=WYK6'XIS$ M$$1[-D=0VS+NL$FC-]$YAJUL]'8PL_>L&KCM$)_64;VD-M8#7ZZ!3JE'7%4; MZ-P]P2_6*;E5")A[/J+MN3:ZX@5'R`N,4C.MJI;$/)>^,*)!<;\*N?/EEAWF5[J&E8-=GY83CD=ERO%5WX%/M$ M]\W;]M4Z@8!4Q3".><>/C&$HE%8H73&4WE?9K.>E*1]$C!K=5[1!\;(9Q*BX M;=;8;?\K_/_K;1_C]GPGO?4?WQ(U]=E2UGS(H+ZLZO*(%GD7Z M217A"2_VL_W7*F'V--G=;@FSA^1W34WO]K1>\WGEGHX\<5:EHBO*>G'*:FB= M9E/K&)5.2=])EW@Z-[UJB1W7/@;N^SZFZX'XIXP-"A:W_TSQ:T?L]C*\]"[KM7+R!CTGOBIG<<`X>:J@3NG1O5)Z=+V&H>^@E1A: MKVMH1L_,DAB&S(VC+*I=!-RGJ90MF4>)B:,P6L33MT(^L2AG5+I!%O,7R\FA M\*8<*U.21$:+[25.KBRE0=S+,Q`B-DAB)E(1'N6+0]A^$?B_*C>DH(!=LEO. MV6<8',ZH7L.X<`Q@QJ\H'Q8^F`A-+>3XQCWEBL1C-X(]XI-#1.]7#>4_`&;' M@&[6`^7X`"8UNKK6:AGD0NMU>EJST4V/\X'#^1234DJ1^O7:\M!;5HK4GT\# M1A2ACQS@:[L&"EOR<=A6F=1Y9SWR MZ'?7#T(XI6M9:*#O.^51Q"'^3FD[U_X]/"*RQ`^8D=J`H^RV.OGR7W!=Y0VE MS7Z')1.0=W(_$MARR+6;>LLH).,NA^#I/%QI@NX5S.^PU=\%J18A-G_Z3;\T MFJLQ5<*R@*>8%<9!3M'/:[]OVR&(I$^N-7"]%\C9;C2-IE[&L+40E==PQ8<\ M#+F3X9Q,4G_'?3YTXX."WS5-O9T#OP:4,MSOD@C8>11=H;!VZ7X#:`,#ZJ(O MPQN1=$DX=@3U>T[3#?1$8.PKYF;3":.<*Y[Q_I2877?^B92W*JA`E,Z-B=JD M>:-:D_A6`FJF8,\.DBG]1GYB47(D*\J25U<1:8VDB,(3H,W@W:-UCYH)]S%5 M>FJ%(GNX6`9IFH28XAH+Q14`"1./1_F6BS%'4B&.TBS9VRQ>B!2K#X_VV/)' M(BU]`J8#)9+C@T5[Y/;#7#(YOKJ8I"XV0V2I8V(L+'0*,+$1L*K0\KP9OL"G M<:ZE??-ILVYQ+Z(Y(^C;Y6W9^!$)O,MV,#4OI,U%,$04)[5H<6D,..FE6`&\ M&26#R'5<*X0=N62D4%S8J2D5AQ;(9%LF)<,;LNI3\7RXYTX`)%B&@&\&6N(% M*+)D$.8'G]:+BL8<,[\C8/HA:(O2KL':,RGF+*W`(]1=)T"D#.)LO;"IA5I` M45H@")%EA\/(-[S$7M"XQ>^#J>M+=1I(PAH19&1\@M&W#O.+]8@*!X?2!^U+ M7(CE_)&D"N@;?->-"/C`!V#1,/71:O.PSD\24KYUX8VW0*QP,)$5SI`BL#Z/ M-Q,S"?)82Y#3(#?4BX1F133Y$JL$GX)=3[PXLZZ#3&G=Q<2A7VPK&K,A)B/O M,H0R75^5;T?C(/&`_!`Q+*(L&.:/Q"_[A;(B(.4Z;/,EN(J$,G0]F(0&0#SK MTZ/UFJC>B,;I1R".G&9!<_N?#'V0)4FL29U'\T7V`'$P#1;-Z9RU^0$3TH$* MA"&/BN!LJ.`(EM8JL!?8)]M%#KY)!KY$6%$8@T1;*L+6#`\\$]7:@6!9"(_8 M!I;M0KWVQ#8,@5'"PTMV(Z\UILAG0_(I\+U5/._IXT?G'HJRE&V[P*Y=WZ%B M-O<\9<+I-(`A5`0$_3](CF*>>BT]3$23E;AM7K+W/"0Y`X(07I6E0JR)5!1R ME`?9XEF@!0U=@99`O>@KE!B:E943`]1KTX*Z3>)?N(20#&&4"[OE M,\]O7\01>V'/K[`>8##%=4@[_*!`MN!9O5'O*E:NHU>DV]4W!P/`O0.8]>+C_R>EDW4GHHE\?>71Z-5W1Y?.68_%RH MB\9NPL"'WVVI,5V+>S!@]WTG0#MG0[;[U;\H9N>;4[&EQC?P2N M'Z.V(`YX*1S?IJBWSU^KWGZ;JXD'R[K0F[O7Q>L#JCD"W4!#Z-MC%[@R6HX3 MTD6Q2.R_J.KK[X4BL53O-2_@^U78[%EY7C3#V=_[_1M\L%Z[_OCUMH2YPLTP MQ0*D4>K9@96EBV$C5)\*]6EQ=R-K@O8CMZA@VH#'#ZCLE&::.X'\G+,"\86C M$''RH.(`%"0!T5;GOCT3=VU%AX0G5!]ID\LJN)=HKK!I,O#P*A<.#WFY0#`K MWU*\8..4\X9+$C769&EM+%_L.ZG%)-2QJ%`3SAK"0[E^;[2DD<.$[>>(V'^A M96*AWW12`)Y,.6$%60SK]X940SE7YY)PSK>SZ$/0V%+]F*IPHWT/AA(:^,K: MV"RTXI^)SXL\"!A*1OT9YC^C^':I*"X3:B![:<:>IO_UIRK..A+GME M"9GFV(R(*Y`-09:..O)[^8%_$3SX@*8%:YOB,V3]QZ*70!1GC&?2(I(&"-YL MN\10T9<&9KH_\H1FZOI)D$2Y)X%\678)>%F&,J"7XX>`1>AQ1L<9^AP1T[DM MDTWSBN!D:6])P50X.S?"(TUX4%*"3JD890+M51!Q^>!*RJ[72J3-MJ=L.)@K)OT0--+'H=>7=W)V^0;$!7[@#O1XK'LIB@N.F( M.44V?F5_#P+GP?4\@.!@&V=D%/9M,O[J>&/DEDJ-+'.)@Q M$@<=+).RIY-_PH\S2IA11YV9)I``B8)TI!DUZL(C_<0'\A)^T.7"[77[`X M\%97`)+! M=N.6PN\>E_Z\_@3U[/\H6P9V?O`S< MC725W@5]FQ3%FQ!7$L]N/"0=W\$`-_+]';1YA-G46P47Z>90/1W")@I\O5@` M6VMU`!M!,N>!MF*P7+\,\_!#Y2_O?D(&RVK/)+G.6A%GQR;#SV2%^7EAXH///#2=^4) MDJC\(N@OQ:]!$RH[!!UQJ0+6'&Q"@MHP>;$L$Q8WG^2Z8*?Q2(=1&-C#B^!@IE&#*!*2/9JQ/-W*18];>`VGH'.'`8^#&[9 M[KQ']1_].7^JQ7Q$;PKK"6P9'@-6LQN0`1"3ACT-/.#?(5[2)Q2]$@;):)QV M#QL$SNR27264"8'G!GSV3_@+QIB.9\`FA89;K^&@8SZA#Z9"`)#I_X\^FWK6 M#'<+M4W0'?`:/PP\T<\D[S]1K]&`@1>,:)"A#(]`5+''J(1+,TCN'RG67C(( MTT8G.$04#&.YU2(TB[S"T@.!*2LQ]],&?>0!C`=CX@3>`TY35@C& MYL5D\VHI;9/2-!=+B:XOD1HU!>67+&`X>U@8VFQR>IH5K+/@/G7X.'R*H0V$ M9#[[P6=HVD68!>9I!?05ACP0"D`94WA:MB*-%9E*GCK^*"/?<,$$18*;:J724ABQUU%"N2NKUZ)/38TGGW4.K`FVM] MF@W#T:E)WC,$:86\2(@"TV'+Z2'&7U\%$TD^RH5Y.,2ORPP1)?T2_(L@MSE0_R, M"]C$$*C"AB"8.?J9Q74.BDV/9()T-TO=CG0`O$]*T"@0FTFZLFCQ%&71V)E8 M9P_H*[D(AL,WT5OA=QW`PX'/*1"/1BPN]IL?NYY0*5-?MI"PZ,BV'$YX,2.8 M25>0.\N=(K=0^MV6/0WQ\"/2ICSL;.Y1CH/$(3RS@MO=BIG'K0BWGASH'M@? M_2Q+&U-\BSJ:\*83%L;HV193X9CB!D\.ZH+Z=$_:25"Z3TU5#F:[H9U,,!'9 MIF\HXI2R?^6=Q=Q]0VI`R#5,K!GYUP<<[!;$;.PZC"WA@%9`TPOSNX\2Z98' M$3A'.P06$6E7H!UBAV)LLXF]A\N7$V+Q@X)]:,G@:5!/TH0%[+J'H1<(=)GE MR.#5K#]R=A^3@73)KH?E;63N-U,KP1O>\`Y=>5D'X9?K=> M,ZU0USNS>U3%/;OZFD=%%2]0U%5BX$II5VJ1UGI13%W0@PZQ_A-#SSVW[53*S!$* MHF7*3O7DT-]#3!BD9(MS$$+[Q"M%)N=#)N\I@=F>[<_0/_HEW^%]OJS+W<\* MAB@FH9B$8A++M[-OV\DD$3=*Q2!@13.*9A3-+-].##9Y%P0_SDBP*F5;\03% M$Q1/4#Q!\80]\81J$L4W$0GRR1TJTCA`W],GG-&5ZCTFXO,PQB:/(-\2GTZN MN]&1M$O^>1=XGVY+U#L@P$9;ZX@F+(?8YR.[PU)H?2YH_<;0C%97:[9.&:W? M*FQ6V$S8;&IFIZ6U](W;,BIL5MA\K-AL-#2SW=;T9O.$L5FI'`JM%]':[&J- MUL;18E5%Z]>';ON4/>T5<>)4-/A'>@;2HDA; M6OZGCW4J8F=9Q`X67W0'28PUBD0GI,"/QNYT;>EA):_.6EXU5?B.0N_JHO>; MAMG6],8I&QO*,Z20>B$XK=?N:F;WE(T,A=8*K$D5L9L@JGY_TS#5WK=DZ98RND5DA=AKS3ZVF=]MD;KPJY MJXGW=`=K-[7:!M]DW2=W$_ M+1B)MMF5)2TIQ7'_^ILA)5O^2&([4F++O&O1Q+&H(3G/<$C./%,D9=11=FJK M=>L0CH:.B]QKSYDSH#*@>HFT&P,F`Z9CZ=1K@>FGMMVV.OU>A3'U]$F9@9*! M4@%!`H..U7:VCHTZ0B29UNG?/J30?3PJ)1RT#AXO8/&FS"F?C%'B^WJ+(W0 M%>*%R:W/#F)MW)IF<*?.O-::V+(M>S>JJ$+GZ,",FL&3P=.SJ9=MIV^U>UN' MN!TCGO8^!#$P,C#:[B#1ZO4&5O.9NS4#(P.C4X91LV6U;-MJ]IYWCGC@,#+> MG<'3B^'):?>M3M?@Z3EX.M!31*55ZX>(CW:FO$/$18Q9LQJ]?H:"38B,:,T%R-=<+N(Q9( M1A1?&/-(',*+8AJ,.`PWH5*R6)(IE?7:FX[3!:^A3VC@D3>=5L^RVS89AH+$ M8P;_"L;(!`0?2\("#YKZ75'5MQR+-&VGB8_5:_`3_"Z8C)@;\SOFSQI/G&T^ M9S*K,H'OQS`A#.:`!VJP72K$C`FT^(5,F<(;A M$=\/I_*7'2O9@;O[`_`A;5@\M4[)F)I*M"M9F[M-#7&9CS6E79B* M?_U@Z]\CZGG9[ZEI[2^%I^]+5]CO5BN"^AWU:>"B98K)!7/9Y):)S%ILX.K: M,R'^*!?BTGRA4@HB.65*W+?Z_9;5MK<.'ZN*P[/?]>ECE]M5,R`?AD-P(NHU M6/Y@U6/P/N(F0K#`G1'J_97(>+('M\;1QT"84**MK%49)P'=KM7?GO6[PK%$ MA:23/;;'KIHMRSM#R_NF8LR7.GTSO!_3M.Q MS_[/MFWGZ_7-Q=>!\Q5!9[=:SE?8P"4!UP]Q&;;AD:]_7E_\0#SF\@GU)>[Q M_GW6&H!WVEWT90MYECMP&3%!8]@S?@K<<,)^"Z4L4^"6W85_[(7`&]Z_+"!\ M+AB5#'9IZK^?@G/7#1/PK3[3F=H^ESF^[5X71G@A[I/2+`M_37TFK]@="Q*& M:B;_8'&9\CJMKM-J-?L+@3=)L#K`\,]1FX%>M&?ZK5LACE;WX\\?%I9A;/+7,_K-=!ER66,)Y9X2*E/ M'L'R['KV^.0A<.6.$#O+1XC;G'[UFH>P@7M)A^QA[!<@,(PFV&*<+/AC\R4L M9&GE@QX>I_G>8[]MQV%M64M5!Z._AZB_^8L$H\(;CF*>>]:9+2H'T MA8!VJR/!AWMV$MC>_S3LN$Y:BU0H@X^3PL>N]^8GBH]"RD?B2EBE*X@K.JW7 M)A2TEE/?5"0PX1B;).Y8=JMC=4TE`J/655+KMF4/'*MU$A6["ZC"4[6E[TLH MOIWQX"P2HZ!VQD3:OEJDK66WVY;3-*SG!E4&5<6M^SV[9W4Z M6Q=XJC"J#H'*L!37P>D;+L/#,@,FH+W<@':[;UNMIF'G,'@R>'I^=WI6RVY: M[;[!TZJ78"A*"HH2IP*CJ14="8U5H+@?3IG`J'$WQ.AQ0294?&.Q!9H1C_6' MMXP'HWK-8S$3$Y#"(XE$B@P59\Z%C,]X8*4_A4E,)BP>AUZ#K)S]P]L##[ZF M#SD4KX:$?LVE@Y]=/_$8F=^46\2GMZ&P-,$)]#`94C=.!+X\O&-BS*CW&,G) MPUE1CZ6%/)SDNE)SGTFOW6JWFYBR7G`@KI_^-JW^ M4AK4)AF6!7U/Y1BZA/_Y\#WA8%91E9K$Y?1Z;;O=7HB_BV3+ M??K"<.ECWCE@BX[8'PG&^UX.K\=@-N1E$H/E"#!]XAV5W'U^IZ1J=RW)R^DV M^\U.L,P7)=@S83.BRP5),VVTVD^EG*WC83+ MO=1L#9?##_>N8C.Z`OMY&6Q6@W+3'P=YL[6+6,L=^DBY^'_D7UI89VFR]@J/ MZ6N_8M8>3C%1$\B12W'O@$D0!/""GO(K`/\$#JDX*?.<&D9?@9GI^&B>^!"PM? MCB08(`)G-30N8N[RB$+7&N1L5_4:=&O>A0:Y01+"U"M1?0DGT%CZ M9QR.A3CSF4PG8RFME(PYK,;"'7.7^@0K-OL2'^=!!"NR&D-L1#,AZ@U!Z(H5GIOI/T!/FMM#/2"N]57,]SRC=(L/4L>T?-T6OST_`LTUY'$8; MC[^_?+JX^?47TNQ%*P?5K[!'W^9$.95WL"KNP].Y`X5A:=UMVLWFCAU>[MT+ MV-??$&CUFD/F,CNMMVH=U4CC,F\EORF=@;,E'HA<4C^V^D^O5Z3S(7-.%KSK(5PW@)+O;ZLJ86]1SN" MB^1_0_&M7E,L'B3S$9^B+-WWB,C8$F-+C"W9:$N:^]H2R2?UWX/^@Q!&&=MHR\Y"3WFGRD)\[Y&S-QQP+\GZ:NFX*"` MU?%]$'<4\"&\%08Q[U=!T^`DW4HF[A224R)@_7ICCXP],O;H1>U1ZQ%[-%)' MR6A-AM!0W@3D<8\6HU[##=%#F$=3L@9YO&'0F-]P8G$SABTF28+<4_D&!1OZ MS(5&$T'"*>S<8`_+\1Y#;8KRW]QV!P=[T#%;[$P76[ACL4C'=WBAR/P7.]S4 MD"83F#+^-\XD3&YZF)'NC#VU$@GFHMWTLN,*O1PQY0SC'Q.A;JQ`3SDLA[G8,9\?A<1*TNWE.`J?] M$H?WKTDH]0PRV],),S5(KR#2L1Y4]=E'TC.X4T!XD3IE(')J$#F)1=!`Q$!D M?XALB"TV$#$0,1#!_CPCB>K4`%)Z&9I.Q9+[,>"Q7F.Y2,PSK"')9MF),$U+ M+>RG?R;IJ,I)1R66V+:M9K=E]9Y96ZLB24<&3P9/S^O-F8&1@9&!D8&1@9&! MT:O#R'AW!=.S=DZN\-.>6#\!HLC!05T('S$NC48;C38:?=@#;#3::+31:*/1 MU='H`F@H3;S@D5UCGTAD<+Y4)SF5VF4&_`;\)H;%!`N;,"\#$1,L;"!B(&*" MA0U$#$1,L/"K:Y0)%C;!PB:[VKLRT7H;GT4(/#Q2&V5"QQY2$*&I'[S1+K`E!/J4<_S"+K+12#_/QVIV= M\-`+>>G1B^D]86DYIRF5Y(UCV8.!U6OU%1OA&V?@6*UV5]'?(K=@/!:,X?%! M/):$!1[RY2YSAZGG,$X`BRG(B"F277^64X4;:(>I>BY(OXL2(`VGK->F3#`8 MMT;G1]5(J]=P?GSDS63]Q?7:IC<_KAR'!KB7J?QQZ.JI*4N#4$RH#R8Y$5(5 MV+C%:G%,2HNU(EA/$!^&TK$W;[N.,B#`9C16ZYX]OD)BL"(QO^W1U MK0$:8N6I#2.O9%\:61PR-7PD2D0$HDDE#&+<'I!G"%.OP1"*,!(X^F2$U?\" MI`K'=^8$FD]7<0;DJ,Q!F>`&)RM@"C.Z-B2J2(3%RH2>*("ZK@@9T`!`XFM% M6!2/J=?>8[&98$8`Y*`Y$T6?"__`?$F.-6,`7QD.^!!LA%K>)B&L,#[_!LL" MJC,\$81I;1^>*^^CL162)`8L_*T+\PR3&`L1:9N2"1&PF'AI<34-QK0^T0+; MJGMHHO"[8824TXJ1&=Q.N^VG! M;/W^[97Z!?^]6'Q\\?8?2B87A,.JATL-9X9S42))F[H-7U8V<4SO5.E!5:W# MTT.F)BV4'-=9L%)W2,7O@IE.XBF6V=/5.0(VHKJ(1_9W>#4.7Z(&434#V,:2 MH.OCB+.C#,:4(P/W`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`G MFA^`80(W9O@J2R8),D]HYH1W:/C.KMUQZ$.SBU3@2>@QOT&0B*A>F[]$@`2" MNY@+KM_')9DPBDCW,G8$=9-SYBFN`_@NTYP-\(>T%XL^`LX3I*LW_ M'FE!&P?(3/#A3O!.>2W[!?.LHKU*%Y177(*O.<1%@N/T@:>EJ/"*@,V1JYUJ MTFYTVS]6Q894=I:<1L?9:9;V"7&OLAE`%A[<'L*>,?0I4H[%,V,"TL.\7J-K M&QM0O6DRWL##9L#G=_#UGQ2AY3^,)4BOR8P1J-(,&2?@(?2#^$B4Z9$99_Y3 M)T8GHUQVPS9^0/5F:>];V->\#=BGK9Y=9233!]NYE_!U'74^E=UIS2 M&5F/@UCJ*[`YY:8F)/>0_E==<6T0.6TN(VJ7%!G4M`?[1: M78.*@MZ<3[1**9KX*Z88OU&;[!:Y5BU<1GJ.X;O+-^3D)VPF3_2LFZS7LC95 M*^HR?8D>>\MK47V:K904NJ7[UK7:?7O].'[+L0[7/C&!0!LC*\,V[FN\=(B'E+G^D@1THZ M=9>,5][J187#K"!S?3@@0WIRT(9EVZLHZ84NXZ+J&]RK:WL8]S?-1I],N.]G MS/H8Y5JO)0&N#:.`_[UJ1=T09VUA;H,P.,.9G&MYJB$6UK?`WS?%2RQAX/K\ M:AD#FH%^`9]Y2]J`KP#H?/GA#39D$V[J-3XW$Q$`0BTS7.KNP7]9ZG-C%V\9 MR8V&TE2*9@S[PKPS"A_0T1Q",(C-1E>KL5D5MO1(E-KA30=8)Q;@W9GQ9FJBL+]E`P3?Y17;CNKQB7M8K0.B0ITV&9*Y#6;P7>=-K M]!Q4%>V06ZJ>R6@DL'X&0U.VAIL5G1XT!EFWM'7=]%Y='P<[AP&C@KIQ`J"$ M+>$$6^PV>OUZK5)FK60M^R,,F%J,44DR90+'9TV7UG4#OK5QJS2FGMJ=G$D6 MQ[XJ>D.&C&+YFBNG5+P1ZL/5??2&M*H5]QF\2X0Y`2 MJV_H,$Y\=_J38-15[_#FA:K2;C3T#FCI+02+W62.D+8SP8I9`1&^*WCK3>V$ MBF\L7EB"A8JD!7+5LU7[L7TGEFQ/U3M78N MTGI&5^R.!0DKL][.6<_I=KN]Q^KMK$BS+'S:X\]4Q+,;F&5)56FN8ZRS4T#9 MTE:994O3H:[7U&`;:[Y7M3@T#7'TL(5%]9> MKHK.Z:J52EWK-:VO%E&7,@PKA*K:=K"F*N)1N'_?= M[R,I,'BP`"O:?]&1+R0^9.OXL`JA5S7Y&SKR!I\;^##3S3HN`1A)3\YO:1`2 M5#W8VJL2S@5AM$K#=LWO"\'CEO%:54/C1QYP.<8=P2C$*PB91%$A>E8U>/Y. M@V2(YS1X&*]2K-5(H7.K1LY`<\,!)KAD9K%\UJ)`I_4:;GV%*AYOP+EYF'Z= M43\18A[^LK"'TQ+*C'R&+$5N[Z\>S6@';=L9V&!JS%Y)C`5^A(G=L:L#XR3-DU M8+W6LO&.S!X\&2>PPWEMJ:*OR[EGXLSN]VX'/;F_@H,4"NYB,`GX3$L7OV.J MTD2X)BM35V06X3I>9$$B:C`FPXWNYB#C^LUR3`VSB?#)%`&'G[$^(<[Q=N8 MNW+]A('1RQ?1>,L7)<*%]^H8F;PT2Y>`2K2`C<*8JZAJ2GP\S]42K(0G=O6M M\/<$(WR&C*D;QG`X!/_9(CZ]#<$_#,5,Q\5,X4OC,(&F'CG_3.,!R3`]M2+Y M0RMX?W8'E+]@7KU\MLC*4&.#D::$%ZBW3%]*XG141&5&&H4>HD;I]QZZ19@ M0^BBT[!ANZYC%WYM;U M9X?PZ+OV_S5W13L-PE#T5\S>65M@#I9*,MW+8J*^^+S$41V)@H%&W-][+RT4 M$!42FY#L82V]AWO.;J&$`^NY=YA/@S#T+PVAB7EU2=T)B<;EASS#YTCCZ_-C M(>)]JJXR8/2VJ6V;EB1&@[7G&DKCL_K+5U7]K<=]?5]\6Q1"6F7B!'X8_F:M M&DI(D=!9723Q-*\4!D,X>HOE6;>@C8\%R^0Y08OP\003]FIQDO)]0TA9EDNX M6%R^9!_D9G^[B``9BBKPO34G)JP&)AUDKNSI9C]05[G[H76A`L``)B9```5`!P`86YI:RTR,#$R,#,S,5]C86PN M>&UL550)``/D-JA/Y#:H3W5X"P`!!"4.```$.0$``.U=;7/BMA;^WIG^!TH_ M$R#9;KN933OD97-+LGG68#J!MXA(XOFE\?6KV'J]O;YF^_ M?O_=QQ]:K<85`R<$K_'TVKB<N>-T]0CV2H":'A8!;_J=$];G9]:G7>/W??GG>YY M]]U?<6EL_=N3PZ&!L"F_:$["<';>;K^\O)PLGIA_$K!Q^[33.6LO"S:__ZX1 M%3Y?<)*I\'*V+-YM__GE[L&=P-1I$!VX\RG0)NA(=IRP@F^WAG,0^+R$S>8MD-G$=!@^MH65=I:K;?WY3#$FG\_A#AF M1!_]T2="\#DE.L&6L!''/SR] M6U0R4^CY(3"*P^$9#L)GL]6#`[]R^.23'[SP6^JAYG/#@P#?;/4PP.^#$/AC ML'K/JR[YO1/.&?1'_9E0U/CJ^>Y$2O52-;'ENG0-W&5D)CKM4>_2X83W1P,& M7.@C\?01%N&E'[C?JB"^`XJJ!?-`QA2GMNO0L.>ZN`J'N,@/`I^X!&M4*0S- MGJL6P">'L-\=?P[7A+M^P'%D5LN[N,.JZ2:=HGX)IC.@7(ZX(?C"AKL*.+Z9 M":IY')5"W[_*6I4*9%](58OLQF$4AR8?`),P*A6&NK.J:=[29_P(V&OR/BIE M6MA?U60_!X'W0GP?U>^ML$3'Y,F''N>0'HZ5TB^)H&J!Q"J8X_1R!!#JX1,V M!^^..$_$1SL0CB697:%4+2+435,21A`IJB6Y8*%??#S)E$10M4#N`CI^!#:] MAJ>P4M[Y'56O$(7?\.@LCJ80"_JKFFR\V**#%[X^,@>78%=:YD?B7J;[RDUB M&(O/(B*X$3T5O583JHFPM-?` M'`FA9@1&HD$\*+T,!E_$X@*6'2DQ!!EP&SG\24;=YKPU=IQ9&T=0MPU^R)=/ MQ)CJMCK=./CV8_SX[[7EZVK.1,QDV9/O/(%_T=Q2N&T0]Q!<(,\"S3V$>NAS MJQCB(`R%E28%OI6`HKQ!]"DS1PM]3GE#Z.?3N53CUS!C@#-23$;\VX(1M]= MP/FG@`$9T^@MNM%"&"G1GO>?.9>6'\ZP_@B'ZG8Q':PG(Q+S/*G+4:L[!"?H ME3,CH>.K6"M*&T$N?3@5T.A+<[BV:)1,&1,H1\$E)=A0X4T5U^;P+8>Q\0!>;-P_;G(&]F"6ZNJ&4YQE!H1*;&GBIC` MF)HW.%;E\C$)?`\8%\M@^*K`O;6:82[%ZJ\F7D\Z-+D%<$Y)TXBW:F=%81.X MI0XNL[(45#"!?\#BE6ZK&9A7TA#B&;I3-PNQ)0O99;!XK.O4-,-($17XS-`I M5I(IK%0K'NI5JK"*"0Y#"!U"P5ON>&<"/"/B$A43C8HF^&BONT4K;2INWF-9 MZ`YSEPWBGQM!\VR::%RBS>?3*%K?(B%,E_5'+)ANQ"26G06J<$`C8`A9Y@._ M[W2:C1<@XTDH_\?_9HP$#+E<-$^;C3E'<,$L"LG4E5WQ)$K(?K"9K*;WLV+; M[=C,MIPGDI#NO@72><1.;2.V9E>D^6F&!I.):]U;+2!?O#N7<'Y++SSK>R<< MS]X0Q\*X7T+YW1NBK.56)-1_LH>Z;B`F+8V\@$>BOW]YV^2+?/I$"!898+L( MH6#C8B6#4XO,LGUDH-X\2$1AT;*^DT)0Q.<2`5BTQN\B@+Q2"7D[-:*&9;>> M+Y;H/XOL'6W*JD2GA+5%)H\>:]7&>D+93E.G@'+N[DC"UZ(P4JF!G9=_F+#^ MV1[6.G%FK9!:'%]/K/HW+(3#)4(FXLJL>JUZRTMOE<_=#DN6>8O6/#V^FRE@ M"5F+ECH]LLKLS82S16N=)N5FT5NK)2V?_+Z&_RWI1[[,IV;LTZ@)X M\[(,,^FRZU-G2]I[40TS";\<>Q<[,OP!)X(2=;:4*:3"-X_#L:HDB(UB9I+Q M5EH4%4YT_G6.NB.Y2.021JA?4_;W%T*EDKBE.**!A_*X=;J52$%]@7`2>&+# M(=+`*C$<$X$Y"2/N^#U?`D5=K,Y\S"]M*/E4BC?"%`.Z1R47O1DZ+DK@U*AJ M@A/VFPP5!?AL&2.)>4LQ;<6:5])8*F'.DI%GFT4'D7'2%EIJ`T!C1,QK!@Z' M:X@^BQ(3C]&]F;0N#F@LBIWZ:W@&/Y"^;#RIE!E=176,)',Y/O`X4"?79[7V MR"UJ&K,>W#H@?0#V3%S0%'"ZM!'DX/LBAP@7.N:(NUMZWI10PD,FC>7B8:Y9 MV:COIF%ZIYVXM17*RL2CDI2/MWA8N0.D\B>RL;`U[\C*1!<=IEM60RNS7'1X MZ^I)*U.*#;BA&0649V\KM@K^%62!(/5<1BL3P7,]QRSW(XK>RNQR31'FQ$H4 M>>4UW[8K<.,SFGW=R[`R+U>3[.92I]C!KOF[5;B&JO>:>+Q6)M.79)OQ0/?+ MI*_!!L[FI>&UN<6E5)"L5!,F[[LH%S+?5LL,D^U9*DHZ&E5-<+H9C7#L]T"TEL"L36B]7CW8+$\7EGDUZ3KU8"&CT*X\M@* M[U?4K%P/7O%!R.7TR#T0J%;B?.OFT-FV_[RV,[OMT)+) M[`S:>0?+H46BMU6E2)7^A\DJ?[M2D0/]#Y/-1FJ.E7=P5R"5C601*X_2'5HP M&QDG5AZ)JVBXY&5/67E]8B4*6)$3L]]EBZ;RN]6_&G[OA',&_5%R;L?L54)J MI)=S3BAP?@W<9606N_7HT!+>'Z%]P<7OC(NGR<^=UY3)`QE3,B*NB%A%ZQD. MTD'@$Q>'6.W1?W((DS?0)3\P7W_0"=;^*!W^&(*\,$R>TTD")*LH8]UI+>\^ M&P"3Z&L/>!5E2%Y([3$O?Q=%GE?,_BZ,12S6+&<1$=VP&BVB(Z[#)-'Y4+'A M*,^?CH&Z=K%(;PS6'NS*7K1(P+%^'S@L3-^H8=,8>8"Q^!S"3&Q@T'$IZ!_; M`M(3+FKXS_\!4$L#!!0````(``*'IT!?_&`3=A(``#Y>`0`5`!P`86YI:RTR M,#$R,#,S,5]D968N>&UL550)``/D-JA/Y#:H3W5X"P`!!"4.```$.0$``.U= M;7.C.!+^?E7['WS>SX[CS,[>3FJR6TZ<3*5N-DXEV9>[+U,$9$^"("M`3N_QK7<>4NPA2O_`!/4&O'?W4&PQ60]SYH>><]DXV?HI&!0%Z#G2! M/QV/3@;'[P?'/SR,?CP]'IV.?OAOTAI&__IH4=0#L3UZUG\*@N7I#TA"W8 M?PU6S0;LIP%H\=WHZ)4Z_9_9`S\2WT5W:-:+)#X-WI;HK$_Q8NFB?O+;$T&S ML[[EX:\#-@G'[^+^WT]\.UP@+UC]:WG.I1?@X.W:F_ED$4G?[['Q?[N[SL!@ M8UG!$RR&)0H#;-,CVU\,`^O5]_S%VY!U&4J-/MP7PQWT_'(?P`ICSYC.KK`' M\XPM]]:GF#WBPK4HQ3.,G.I0),<_))A;BZ`])J?$0V`D&,1RZX=W#29I@<9N M@(@'R^$9U8)G=]3:!;^PZ-.5Z[_0:\\!.VD'M0B^.VH]@M_X`:(/_GJ>UX^D M-U80$C2=39?,K,/4T^I`2CVE:6`K%IL@:A.\9`\=>\ZY13&=SFX)HLP>L5\? MT&MP[OKVUR:`5Y"B:<7<'8MH&S`W`);GT7VQAZ-*D,R2P,IO%G?_`IN&F#P7[XB^6R*/1BKM#+O/X+GP*,_,$9AY6 M);/W;U&O1A6RKTA-J^S2(AXL37J+2"1&H\H0/ZQIF-?>,_SCD[=T/AI%FON\ MIL%^\GWG!;LNF-]KYHG.\:.+QI2BS>78*/R2$C2MD,0$4WB]+":(Y\`O)$3. M9VP]8A?\0'0HS505I6D5@6U:X"`6T0.S%!$6[*(/IYF2$C2MD,^^-W]`9#%! MCT&CN/D/:MX@LGW#@_5Z,(.8\[RFP29D"QN\X.V!6$#!=N29'PA[F</:+#63#E)>0,D\L)BP%X4U/H,DF5DAI<,>0Z+"L:_ MLJ&:B7%&HH`P\$IG)'!9@-@G7+5%8"FRC^;^\]!!&%0W&K'_PTS;:'`\2F+` MW\-/7\;P:(<]_LJUYJOA7.L1N6?]W;\/&Y?G(B0L;G@%%LUR_X,L M@PE__3=Z$\FUT^Y@\L'>S??N`W#CHL`.G88!.X)D1[!B8?,Z'4KR2>+3"&2< M;#HMS4MSA5U$+N"]F_M$/,O95H>2[0[-,875Y04WUD+X:FPW:UZZSVANN?&S MQZ^89X"W6S0O$^SRV"J^?UL\^BY'HNS?U_*D#MR89"4#[V\U3.((RNUADCXS MXB\DR&CU2)]GZWH^<1`YZX^.CX^.X7_0.O)M3]E&#CEG_8"$*/W1]P)P.B_= M:/\'3G.\`>SWEL`N!&;BK'_2[X44FL`!2B&^ZPS$':\Y!?E#QT!FMC`IS/>MA[G%'2FT'UL/C>]( MI`C_U1&$.^YZ"O&GUD,4QSM2E!]:CY+KCZ\!CHX[`C!_XY;B5>3@<*.EVZBY M6_85S)W=0;I(5C\-LF/@PH6/)G-+*&[.911\C M;8=T,+>L9;P[0VY`5[]L;].2G[]L'<@GUFUKSU;0N/J&E-'K.Y5\A7BYRP=8SO&+=3)EA8XE[!#TQ ML_V,XM7WV:?TRB<(S[UX%NWX:-^-X(R=_X4TRF6!-VPZ@Z5:K*;:GJ1$8XZ# M8YJYM3"\H!?6$@?6=NBKJ+42R:.L-)&@\1_5R35^9#LE6_B691NID[/`\F7: M*)=22JG;;55(S6HD6"X<_,,,XK/E1MEQP85%R!MXZ%&FM0"%7%\EJ,2)?B(L M.3U4(4AV3;E3L-U,A:P3-$.PDIT[](R\L,"_%3360.X;W[/+B+[17J7TP,>Q M.2ETSO-Z*$:PX;%*3X.P6SDLN_F-[!=XRI)M'IDUB-RF1&,BX>3Z=.7(N?J< MK]+V!7.[_K,*V;;K".#UN'RUW9!%J@KDENJJ!E-2)0(2"67?:-*MP_3J>MNP M+/`V1P3[Y+L.(I2Y.L%VYH1T-QVQ%#BKTMT58\LG/TUB(KMBR&M?A_W"9BE) M@<(Y+55+7.A;"!JKD#OR(,KX13D=5,A_2Q(_K7`3PVNI2.*EA9W+5U9"B[). M7/Y:E^FI!I$@YOF)^%2T%2[HI!4.L5>3VT4%ACL4@-.-G%6%?\=TM^3D.E\O+RK@6-U,@IZ6MJXEV6]B=E/,B#Y33DQ\+9>7A! M?'=].'ZB7_J;/+@BHDA1ZI?]5F(*:SN03/6A7\I<#;,>T6J*4;^DN6*,DD&\ M%*1^:7/R$RD7N4JQZI<\)X^5@^>=?KER97EE$XU^J?Y29YR;H"2/%5/,^M4` ME,:G+BYWK7$U6!_:\:+#.969U8,_)T]"Y^*Q.Z.(4"9WK MTFIYZ07'-SH7K=6!.S>%3>=ZMCK`Y[76N="M9I839![H7`0G?\[-VSIM5\CH M7`U7&:FHHD-Y*5SM8$6)H2G25CAK$DBY:1$IS%;X9?*KEU=-E8)MA2Y M[Z@B;VOGQI7BX]@LL68/03MXX4HYA6S'9],)UM>ME$,F[X.DF!5YDX4UV/EG M^!H78LM,9AGGD)M4E,3VFZ\JJ;:38-563 MONYR.37)9(BEJ/5UG??=ZV^BE/.<=;YQ(OO-+Q6%J:[KO[!O]<'[-?'#QV`6 MNKMGE07EM:7&4%PP"1J?DFARG(@]5M^"$6"3Z:D847QQSC@,GN`]^#M=MF(D M.SVT0'!-:2@O?=):"\G%M\U*=>E*X5\#TGPY,45G7.^^I!F3[*P>EZ0Q*^BD M"XYK#\-L.O$MS#JI,XL&V$@](A/DK3G( M6VX'U(9<(CG@L@Y%&S*(JB#>=37:D#!4'>G*&6E#4E!UE/P+9#7.`Y*#*A7! M:$/F3VFX>:^ISD<:E6#NOJ,ZGVA4@BBXX5F1-Z7+Z:+R('5\TC)V`T0\*\#/ M2$4TFG/V4W"!:5X/-;%!"D]G96CTWG?%T9\Z'H+(IN`%1-@$]1S.?H(TLQE^Q%W'WM0?40)V&0>[$^IXC#[P8\?V"_-:*KGB,U!O+E`AT`^Y2 M/#/>/.^:1(FNYB0K5A;H(EV^`H5FVRBY8FTU=86R\EHJNQ2.XQ#S4J>`#>([ M37(3J>*/G,$H!%D435#\KT@-AWJ\3KIEDYTO;@%EUS"PF@O+*((]-+O'88*> MD>M'5\,DAD\`-;^/DI,WRT4T*4")=F-B"\]MJEIF.7%UD/0>D6=L(TD%;[96 M(CER778[#C@CQ'+9S4_.`GO15P-9:"1_F4MV-B?CW;F6[P\@N">VT7J&*9^C MFY!%3:>S9/LEFTM1=A2-D.X(EQ?E*#>&N@!W4=0I&^;>BONUH5:H#,`"PE=> M)E0S7%D&:$-Y3=EUG(T*MZ&X1BI:N0E3$)0M6UK0"JPE378;[BR5C([FS?@Z M%-R&4J$*>$N[).J+A[Z]"Z_JBRKL7`=UD#B0\FI$DPQ9;[8&/R#2G9Q'84BB M.TF.._&A[F0UBAW9[N0T-WS<`*3F>7K_:3YXVI*"4X8YJNO:T[G<7)P07]]$*3 MEHN7!K3151M,6[?Y5I@KP0A:(=RX"K4LM,VN>F#:NE1;&M!V/SW0K+XD569J M-OOH@6+M72>7>!9X\24&T`0?VY&E7]^H\C[E#*$1QG2;E'R5KPRZ[\PG;P"]\56;S[R!-,++">V5P\D;0&]\U>93MQAH.XHD84>7 MQ)O']E\A)BCGL^A<""4&4',IIF\CY$3'[M$=-M/HC(->OB)B8YISMV=1/S5% M>\M$W=/9YD>)!""$S964`G$C7`+)!8U-R55W2JZVXI\EWDV9GNI.H)L\+\Q^ M?DWF?$-Y@J]&&A-9H#84$!QN516<_ZFO,M!'6;RP1!LJD`ZE'RD3WX9RI<,M M*/G8K93)/FA#:7[UTVFIDE!]=UWU`&\F0-:&N[EJ6SC2 MR1_*[_,R=[;47DA>_=4XT9=_]T*?RTGT-ZU[H:E*TC7N=_KNW??!O5,7G`)6%(SZMBOP;_P`@;N6V"#+78.D-U80 M$C2=I9??5*_(UZM"M&.Y_KOSE!4TIZ')L6OK![\[$2IC+\ MRN?7\Y#"7%(Z0=0F>)ED=++[M^AT=DL0A4;1)#Z`(.=@X+ZJN!&G@I1\"UEA MH*[<2-$M?\/PM^%OP]^-\'<58VOX75-^O\=S#\^PS0X.X^PT[,UO?1?;&'KL MS^F&XQKD#+FY$W")7&?#W8:[#7=WAKME38;A:TWY^LK")#J3F&#*5FU(.DC3 MU4UQOGKXECF_CW$V#"D;4C:DW"`I%Q@MP\6:,;QC_FV'\OO+SU+WRH3&=V^LYVF';XISNQ@2-B1L M2-B0<*.?;,XS68:'->7A3[[OOC;XR'EC>'`/J^-XWP\PQ&_YT[/&LE]CT^C5Y15+X=K3J:B98; MJC=4;ZC^FZ'ZRF;7<+ZFG'_A+Q8XOCZ/78_C1X4"R+/UH?J2$O+-9\E!#+$; M8C?$;HC]FR'VLD;6\+FF?+YY[WSG0N_=HC/^5/%9@M_6D+`A84/"G2%A@4$P M7*LIUZZ_9F1.N[EY:#G:X9OAW"[&;3`$;`C8$'"C>6AY)LOPL*8\G%33W5HD M>'L@EDB7=H MZ1-V]F"XNR7<+3-Q`OJ0Z&FXVG"UX>K.<+64L3`<+>;HCT/VB$>+(OB/_P-0 M2P,$%`````@``H>G0$'1)%]D'@``B*,T#C?Q@[VBFN]$-?A\`XM'XYB^O\PR]X*(D-/_VS=G;TS<(YRF=D'SV[9L? M'HY'#YOOZ M5&1O:3$[>7=Z>G[2"+[Y[6^0%'[_6I*.PJ?S1OSLY._?WSZDSWB>').\K)(\ M[2AR8T.J9U]__?6)^%5*E^1]*:S8'?%#3#]WB*A`_OJ]4"?_NF)/-%AM_4WST7>#KL1584)US_),Q\(H-TO3CL&,US8M!D,6MJ9)^20,-BXSA)V= MX*Q:!W',OSD^/6N"K[_^>92F#*Y5>9>LDJ<,C_()^Z98XLDM29Y(1BJ"RRM2 MIADMEP5^9*%=,&]^:5P1%?#MFUVMG:PCY_8ZL1>XI,LBQ5Z5R:WLU\6?LR=N M<9XQ>[SEP/GQ#P]O_MQ80[4YQ.RAVB!2+*+6)/J)&T7"ZO]](WW=;_@5:^WP M;<@Z$.%>ORYP7N)R**91T45T4J2-;^RC):A:XB2EK-E:5,>=QSLMZ'QW`#;. MT?U4T@D\DR^718'SR@T!C3`<#VL/7&E6BT=!'T?7%U(Z(G;T(&(`OQHB)+;O M<8K)"_?H(Z[<$#ZH`H#S(3]LD&EU$%.*`_3;Q%&L=8Y0S@*A4_95B8L7UC&R MSY^=?_GET>_?G:*$=9Z?G9]_>?3E'\Y14J'O&;:?T?G9D1@QBY^OF*GY$RZ: M;]G_F:D%3BOR@K-5#.PR@72(8]H:!6(:[^-NV"O2'#\FK[BTTDPC'Y9CPTY8 M1BQ2`0D-<'9Y15![7@G/X^A9S+#I`=\0+"#JE9&=$^H'Y,.C?M,)"^K5UY(8 M0.\=`([C1<.,F`'`:P(%`OQROLSX7,857K#^F8CI'/8YP_P#?]N9TZ(BOXKO M[PJZP$6UNF//HV*_7?]K219S(S_V8SXLG?;BLQZ\C7FDVD?K`N3<@5($:LI` MHA#Q^[J8W2CK,,4%4DNWN"S?HT2IJXE2"C#A]\J87ONPOTH%;D[&U3,N+NF< MA?',6FDV*I?]_"TMRP^TP&26R\8O73T625YF(J31Y)_+LN(QL#'P>,H&!7;\ M[:TDF$9F7^X[M#>B*-0IJQG[\M)071QJRD-*@:@M4;R$CJ=\O`PV8`"HO;2I ME4JIE61M*9)&:=^\T[1/>ZUWD*9J,B'W23X;\9DU\BI9"YAJQ_R' M*"HHS_;OOQ;FZZ+0(T7KPD0'JW;,[$=>(FJ*1!_:V9Z,)4[?SNC+R003R4/VH4\_ M]M7/(]:$3'@S\B%+9KVGNOE[`-IL%*J#22.#N%!8N._/QT-C5_N(.2Z'PP#I M`,H25Z6N49$_AFRR18FZARI^/`S@*'O9,+:O)L<>N3;2NQ>LG>P\S$X#V+H/ MAS+;>U!7*#CJ;,-F(03_HN#DZ\/#]>,#/!2-X^C-0."@:1GA=F2"`],R:I.X M/.CHTZUU-/LI&TDY)URA))+&TC1HW`@*')].+6A?%@JO;NUI+1Q)N^KF^F4' MQ+"S'B9X:-$,WNHV1X2N<)D69%&OU5XD)2G'TSO^SIE78@'$=G!B"T,!^>#O MG09QC2&D6!+;&H0MOK:H6HO@I,3^(AL'PBN\KE,YAO_ MAV^8>$DR/O20KMGGL^&<=.*#HHY&%6H, M(&'A(*1;X(+0R74^,1%OYP#Y9G$Q[X^5`),*8?8]HZ%TXH#Q/51)48%$^(1G M),_Y,SQLG-;&\R`10K:97DV(VDRZUT0\+>.=0,Y-GA8X*?$5EO]Z/6J-"?!V M_?\$74&50))<4_/?@HAFT=DH:J@N$F70^ M)W*1EOM*<[[NBO.48-UZH"3R-Q<,?]4+Z13G%E(]A[O(E+\Q$!WQP3$6Q1 M/U"LI/E#Q7RX2XIQP5Z`*CP1(UO6JSX\)X5V\.B@&9A_%G<,(*0Y$JJ(Z:)Q M@:2V?)WF(T8D#,`Q;:?(2JYZA!8LM!?=_$!(8CGBK<\FESH`II!PI!PMJV=: MD%^UQ[%,&C"4Z;OA0A6I@UHE<'KX15'3HI1A),8P`.BAPY*&%H.Q1T&'F[)< MNE.AEH:D@73!@P)2(1+XNWC?A3[1N@\&^RYFC)!7XHT"[N-EQ5/U\52%KH], M58$$ON*'!_H5K4@HX!Q'EP?4'`@8&080961$/WQ@6AB7Z/IB,/`WKFFHD#_< M^IH/RAWBK^VQSW'*&S\Z,_?'5^=/;UF7@;9W]^ MQ12^.OU#MZ<0/RID^?=+^J1#IX96P`L]F^=V+S:H-&.XV!/60;PP8A@0E\^`[2B?E`\WT;Q-=J:!@[Q2M148IP"SD M$!>$ZDR7;$0HZ6:85:[Y?<`X]?S2(@RY\-V.#@BR?^VTR[!H>14`>T8PWH`WZ%9P&V1,.-_3AG#7LZ_U-O0/I$R3[!\X*:[SR552]5]1C:*! M3L3JRK<<#9#RB"N@:_XFQE3"'Y4]L/,ASM#:H-() M')(A]_*=QGP&4R,,P(>N!S;#<&L`MS6?'S.H<3>(%_29V#+COA0P)?=;1R$.GUBM'3!H` M\!]PPT8`/LJI#S2#7SCB'T8S[E_P5,G\LKU8!ST&2`UQ0E<#P*Q0TMD[]PM: M-1A^#/KB0A+U#H58>HMMXV&T0%FM"+J6ZHHM#4?TP?L1)86N$GNJL5G[MGTGSG%+\J!Y32^T%_A^U[J+G]#(SK06?S+VM* MKUFM5ZN;?$J+N;P`9'C=WU\_^(#9PSD=16M5=(S6'WEW(^T@Q="A=P[H!]-[ MC%*Q`1"B99@=T=,,,Q;?@IOMN-RWM@Z_XZ)Q1:Z/RVP=']AW_2UQ9ME`>RZT M#MB@56]%`^,Z"$?;.#H]/9<"PFU MP$.;D%&$1+H)1'VX:^,.A_F[)J^E9@OHL%Q@E'<*MP&C[L+A-GX>RNN0*!Z$ M11^^FP&&P^TC,VNH>_%S8)3R,FV/F=N!QW0S3W6LFVR)Y'=/(697_7Q_./ZXD3(J5(C,-0) M4'UHT>#9?M@E&>J[<'+I@08E4!:!GH9Q`9>4$^#49 M?:^N2+:LM(F<=-*`?*A=<&="K1`'`Q]GJ]R!BPK@:7D3H]FS[^UKP:/=O M_VO%Z'H`MX`:[Z/O!30`<^!(=#V!;7^'7AZ0'];=!YO,@-]HL7L0,5'`N#/" M'"H([*=3G%;CZ?5K^LPJ&=\G%1[GPU<0Z)Z?CXF0Y/#P2P`ADOF"-<>(RDLV0!FV!40[I/.MFL-/<(K-"@27C_Q6 M](&YO.[O@:8X.X7J,%++L&Z#2P$L)^W+RQ!3G8./N9GKW`PD$.Y6EPSI19+= MY!/\^E>\TE7RAEQ('/8+-SWI%:J%D9!&3!P(EP?P.AA.=;#HX'4PP&"X=4]# M[*@4%M'^*7P;H,24D7C?`1TY1A20"([)B3UJ(A1%KN@\(?WMPAL_!X6]+-., MAY^D$-1P8F$5_K5&(?6"CMT2GU<-4'DB=YRL8;(YY[ M7KQ9ZJ:*=K(9<@)O%T?UDUS,ILB445M%W&SG$&+GK.+:-&IM`TWQ':`Z>#T\ MU?7`:8+P*RY24F*>$EO6./&X(7/`W^ M)Y+I'M;ZYX!H;\K48*'Y&0:].S@7"IG]1ZJ"L.,^)-Y&^>2&GSV=D:<,R]0P M[K<\>QH!P*Z;9Q80B272UDR3TBBJ:Y[W$O!FC/SL=4Q<\H/K$.,\*@B"ES+] M\BTM2SZ>D]=1+]G0K;Y&@`UB+_"4%GB=IAF7WY.<%N+<.$,)+BL1H6I%YNOX M'E?/E/WRPD3FAJT0(3T(V"($#$O++K'KC2O+][76"=1Z@:0;2F9T-EIL/$&- M*W63U#-8)V:1#B'%(YAK8**I\B=9I;$D*@7@N-H2AGXL<,VHN'V<.V+9+:R3 M#MX\;;A@QO5:''Q/\$'=#\M++6@V.30<+QS>&5?=!^]&E>#('_;#C!\^\1?5 M('RG4&+HD\P`VB2`(510%CC=HA/![3E^U\S$=EF.G_=W!7TA)5^.8(.+R,9B M3C?DQ'8S#O.GP$F)K[#\]R8?I2E=LF'77;(:V)3KKA>6`69G]%P0\JA19*\[ MJ%%%M2X8+;8*:>W]0N]]0%JX8:M'$(?`XZ+*/4XQ>=F*+8IJ%(1I_=F*,ZWZ M;K01\2S7CT2)Z"3'LT1_,GF'R-9!%,8@X-FS"3C ML0#-J&&W/(G%C70G\N+KF'P#78_:HNVFS)BT\LU0(5'13KF0Q?=YJZHQ$$WQ M9QN&*>J1$6!-##'>?^T#-B4;]\./@3^\R/.=GVM<#94[/&1_:]"]DC(4S M;B'%=/&H,[;,;!D*/`ZJ\*6H.J`441SQH8>B%LV+D$LH1J_A&#$` M(3,;^K'&P81Z<32?728+4B69?471U0`H1W1>^1!F;0/51F)8C=PMSDN19*%$ M)$=T'5W2;HG*VH$-:.XB?YR:N6>LIDB(R.^P:V^OV^8MR&`"EHQ:O[SH**Y= M5.Z4C/#UR#M2&52VOI`Q,\<$R#\K/"T,--=,1!QC&TZ.%6;$PN,13L'5N\-_+SNUKZ(@4W.P.NQR:TR8-@DYUE7/EOI! MV:/WPS(_OHIMQ_C6D8!/?=CAT^6")5)0#IAZ#D4$`N.F!K/!-&!S[^QE+'C5 MMM6]2$#Q^+>"5/B*?NJG030(0F!S7;H5H4(2<5%@H-I<[A]3J-6B@.X&*@8! MW(WP\/GI;O$LR63&L=$K&;J(MB\1*"M=KUC=G">7:BZ8_XD+`J3PW*NK(;+0 M:1YZDX!N*!Z(!E59/QGE$Y'<]IEF$_8HY(EE36MA50O8V-I\T6&E51-SGZIB MG2@`)BO`EO$\%VJI`8R6/9`^.L'A&9+/M" M'$@%OOEEUQ!O1A/-];Q'S$S MS+3AQ:MJ@!EW*==P[`^Y$81A45VZ`U]J2?!.Q^RQ[&::!;1(MIGH8:%!MQIC M'#AV[ROZ"J"X]N@/:HV8VG^W("XWP0ZZJ=$.'C/JX5MQFL\><3&_PD^5I1D? MD`R)]\WB#1N#$!=%7/:P;;D5X,Y>-\A>T$+DP:9393O$A*F#PER/D@Z^-=%" M`[O=H^CPF!1A('BW'K@AO)6'![F3[_&!>A,A.ESW`H2&MFT9=%@6"-BVY<(> MKN&7/'V=E\"^B@C8QG5.?7@0L/Z85,L"CZ=M;D?-4QD0#`CHS=(U@)""_#+; M5A0&QKXNL[''Q;(D.2Y!7R7U@%!!K`D.!,&XXO?;BF6Y"9Y7X&]ZMB M/`R$1+RS5SI8X4I>V]R80!S-:-'$^K=#G2QXH MR;]`TW6DB3'28/SRAFN'=WZU%3:ML?R=J0%GYG2N"HS=N_0F0X9@"?K@%?;D'1M)M;.U"].T9G6 M_:?8WR1CB[K[-`#4@8FZ^HF;@=MUGR9#43)RE^YSB)FQ=I_^H?>[SR&NQMA] M.F!Y.]+&VGVVAXFW[#Z'#,"3=<"K;4BJG(N/L_OTBU-TG^W[I_I6JJ2*B;DS M-<#5@9>ZVHJ;C]MUIB9#4?)SE\YTB*>Q=J;^H?<[TR&NQMB9.F!Y.]+&T)FV M=TCI'[\B$Y9R;<$&-BE7L($1Q,E1>:86K-_=T<>`)-S$9(]?O5#\J)/DY!=. MB'>GYS4=^#<_?Z05+A]I/6649.N+I70=EZO6GBDSH>F2%R#6A+9S2??\N2*J M*%JKMM>#';P;&FH)]A'.(TPXVD8#[A$=FL">+.*4]JD,B/YQW6=;>\DAR8!] MY4#QNBQ^ZT'7P?M-6Y_D[G3MJCIJU&PZ"-5+&9"A]E6Z$$'`S),P7=+YHL#/ M."_)2WV[Z`=:8#++Y<;&=/58)'G)!^0T'^43\5=2WBG*>N#Q]#%Y MO<,%X7>-=O-`Z9YVJ.)#TBY03,:,G)WR&U;7'J#&!:3X((Y-*5Z@U@V1#6H\ M%??;25?01HHWF$$V<%4W]9DV]5DI]9>L;8,V28'YW6GG0CZ=F!I/WJ*;7;9, M>^W!<`0-GKNW_DV9N%O=H5T"GR@[<.6DG],((1_7<'?1)C2U#B"Z7N1U!&U311PU!@;MD)=[<'^DH_=>2%/BN MX.]KU>J.57_%^GQ^R'LQUU/"PT!`BKA[I)(0W"B")Y+TAZC*.<\:`N%@4>=?%LD5[I)B7(@I MM$X*W5NZHW)([CEYI,_.7><@%]J(J:-Q(>=,)TA8X.-))&S` M]%U[BJ_DVD=HP0)\X8J@%/-"8(=>[I4!3RWA2SE:5L^T(+_J&U6S$AB5^IXX M4DBJH58O!MIXQU+3I93!),9@8&BC0Y>>+H.5$`M-;LIRZ4616@&8'M(+/VI( MG7AHX1A#EQ)$&P0D';HHLE%!"3P6&HR755FQ`3')9QY/4-4")H3BBA\K%,5X MJ.$339X.DB!GQ.3U)*@M%"%.](A1]U(_/0Z'=SND;\ M9V]/S]H7BS^ALZ-WOS\].CT]W1P^L;=[VNU!Y.5E+;Q04J'O&<"?T?G9$>+; ML(3$%4[Q_(F]B=7?LO\S&PO,]TKB##2?J`&7>EJU%0Q$)7X1T^`%3.9L6"Z: M8:EF<\=R+Y?N[C'8_%F[Q]7<-Q;'Y8`>@.MQQJD:8#A$4XPGY0<6J*#T>"%V M'5V_XB(EI>%=QJ87E#\69_09^(4>XHIUYU6KHK4N%'5V#$GL(L.U-)^H%MT< MH@OP367.D.MRR*4^@!@T/#7^7:'?2&E1"LL=@R=ZE&D7=9!0!&/-#L'T5G#8 M$"ZE)>PJCA.V>CRQU4!4)-%?AV14B8$@^HN(C/0XV`U*MHW(.P1R5$>2J)$< M\5".D,AC'25)-/L!@B#W..,+0'<)>$=P5)$_)(LG0.A*:@V<>MB&GRP1#P#"P+S&?EV3]WA5^P1D5 M/5\]-:%]:B:=H`0P.*)E@=01HS!%JYDR@^HK=HCDOY+YXD^,!FL]6#8X`*I+ M"5OH,+RH$I+CR752Y"2?E:,T7-9C<@`V+8%;Y@4TUN MSLH;T")#K`-88\'I`RY>2(H=&UY5&@BWB@M.^&WDXVB![=[?LI_SDO731VA. MF&)%QL?3>8D)_QT,=^-9IX2DR MY_W='DZ=,.]'5%8+@BRC9/OP08M`$V-G7 MX(CN//Q![+8QP:"4O6,\TVS"G@'?J5ZMM,]@0S`H6ONEFR9?:D$D)8'6J%T] MELO4I2+^.W%,"':+MAX771`/!AD'D*T#&*T"*+"M/?H&P",8H.P01(-VT$NK M[.@QPQY\M/&8O%[@'$])Y7O4VD4S("$U(&G=#ZG M>60)U;9$L=HQ;%-M$1%VP\&+I"2I'T0T-N#).NR8/U4W*8J$I:B(ZA6L^.W? MFZ1FY#I0U%!A$KIUT+?,'ON;_<4^\.TR[(__!U!+`P04````"``"AZ=`98%? M=G\3``#'I0$`%0`<`&%N:6LM,C`Q,C`S,S%?<')E+GAM;%54"0`#Y#:H3^0V MJ$]U>`L``00E#@``!#D!``#M7=MRXS82?=^J_(/6>9;E2Y+-3,TD)5MV2K6. MY;*=R^[+%$U",G8H0@$HV\K7+T!2HB@!)$"1(@UU7CRA`+#[``0.&MV-3S^_ M3?W."Z(,D^#ST>GQR5$'!2[Q<##Y?/3;0[?_<#D<'OW\TS?_^/3/;K=S29$3 M(J_SM.A_)]]^2[Q],?/IZ'H0X7.V"?CY[#Z+^,:&3WMG)R7EO6?#HFW]TXL(?WQC. M5'@]7Q8_[?WYZ\V#^XRF3A<'+'0"-U-1-":K>OKAPX=>]&MOS&O*.?Q`L_4>*C>S3N1#)\#!G, M1T?)LV>*QI^/G`!_[0I83\[C^M\.B#N?HB!<_G4"[RH(<;@8!F-"IY'T1QW1 M_F_WPXP:HBTG?.;=.T/S$+OLV"737NB\D8!,%SU1I:?5>F]7'>YYS2\/(1\S MXAVC\34.>,]AQ[\C#(M77/H.8WB,D5=>%$F_$\:M7 M;\@GF2GJ^R&B`1\.+Z@2?;9;K5SP2X<]7_ODE0T#C\]\;EB)X-NM5B/X+0D1 M>R2K?EZ]DMTZX9RBT7@T$Q,U[WI67A&CM]2MV')=&B#F4CP3+^T'WH7#,!N- M[RAB8CX23Q_16WCA$_=K'8J7D*)N8![P)."?MNL$8=]U^2H<\D7^COC8Q;Q& MG6!HOKEN`*X=3']W_#D:8.;ZA/&16:_>^2^L6]WTI7Q^(=,9"E@TXNZ1+SC< M)6&\9Y[Y-,]'I9CO%U&M6@'95:2Z(;MR:,"')KM#-!*C5C#4+ZM;S6'PPO\0 MNDC[HU9-<]]7M[*_$.*]8M_GT^]0,-$)?O)1GS&T/AQK5=]0@KH!2:9@QC\O M1P@2>/P)G2/O!CM/V.<\$.T+F;*BU`T1GYNF.(Q%#/BT%"U8?%^\/V0,):@; MD!L23!X1G0[04UBKWO(7U3\ABGW#H_.VMPDQYWUU*YLLMGR#%RX>J<.78#=B MYGO2W>3UM5-B-!%_[]&,4/&![0D"G=[QG3L4_1!>==D].$UO6 MM_S1ESY_M2=>?^T[DV5SOO.$_,]'V[_W:I?G.:]XSC_P?WZ<5V*$:/%J2\FWC5_QB3`JLON M6T[1JWI2IB7W)^-:3_(I`@WY+),GJ+3X_J2-^U'].+%$G.SO>Y)G<0KZ`1EMJ M-IJ'XCA''&>IAP_'#0L,@I78K.OP"=[4U7"L^/!PV/VD:7(O3AH!&2[N96X)P> M-D76,1FD6-E'G*4FIB4X6[M9FS=6N4CD#ZDE+"P*4-.V.'/47(S%EWXCBSV+J#_)`MGVR:>9+'7S9<*9*U<HC5JB`HGR#TJ^YW&A)+RG? MD/3SZ3QR*1@@/@'P+U)\C/S?/DJ\;OM3<_^8L M\D+B7]AHS(=J,4R5O:D1Q#P/QTO-G8/Y!WKIS'#H;)K.BTHW(GGD3Z@2-/ZQ M.;D4'@J*0LW)63#S9846>G4;T4KMHJG2):=&4QHD>]_<+M@LUH2L@V0W<8]>4#`OX+>*PBV0 M^Y8$KHGH:^6;E)ZOQ_%T4DC.\VHTK,$:8]7N!F6U:IS[T$QL'L5L$-&F!#&5 M<'IU;'%9*=_GRX`+1=^N?FY"MLT($/YY7+VY_ES8&PODUJK:C$Y)?`^72"G[ M6A&[G''*X[8VL_"O.5I@GXGO(%%.A2;DOUL>,A1N8F0E&Y)X MYF#OZDT$/Z,LB49\_48NUBEB4;%)O19G;?=*`);<@HV*J_D?+!@#=:JVJA.LE@41:%FY-3D MSRUAS,8<68<5[]%!(-_"+WP$"JS6*X>!,[O<9_6!*5HZ4X3L\IXU&#J5'>^F M6.:YW$::S%??;HQD]!WV`C018KQC,/,93@I0&:];$CK^>QULFK;8%""[_&[U M!Y">\3+%R2[O6WV<)%B\AF,)D5Y":,4S90Y@4%INYM08LN2?8*4HV\VL-E+2LDBE:=@6MF<](*ESL M(LXMC@!H9H"8GG&NCYF\,SE;X]"KP"WOA,K6`/4J<,OQ.[,U;+U*V-3N8K9& MM%Y@\NE4PQ'WH=H;RH=?8^_C3.9;=_V=,:QV*&CS*= M1>JB`U]:37E24HCMW/6:0:P3F)`B9N<.>%?SYCI"93;`)KN6MJ=8RUY/W$0F M%M\GK^*B<#XK#,C\*1S/_6U/I8)\,D9M-)PAA",^HE'G>-%:N[RV4J&;3LV& M-8KS??;GX3/_%OY.AZU:DZT:K=!@R-A<7_JD="LD5U_/HE7%EDP7=F4UR.Y; M#*<-S114:HL>N5-(3H6VR%\\D135@NA6B&XUCFX%9\P6&!GS3SC, M:+KMGIAZH.FNX+;[7Y9!:YL7V.YN61ZE)>NPW:6R/$+RRR@L]:+4@TG+)&&[ MWZ0Q5'G3DJTG2:4@VIZ3;#U(*@6/XG8@NNNLBKT8Q1G?&WBXP3[('XZF.`;*FF)!4>=4F4L3I+_D:Q M-LA:8-Y2%F]"]N49^Y(.7S@,NPK!Y65;(W4![/EUVJ#%`/OS4&E95Y5ND>2& M/;!9RY8CNEV2HZ_\ASA+B./[YARRT8POE&*A91=H3"A:\^/_%0?1^CT,^-J( MF$C5E6TE]@?Y%?'=G"?R?L2^1ZH)=9\2-(?PBED4C%A5Z>8DYX@GZ\8%"M!8 MF:-55;JA:PRB@1'+E`ATRXE>/*:"2=Y5`!I5X3`]!HMCD7YX"D"S9=Z%E%_. MFDEWOAQBA=+*2C:6H%VRY9#YHO)9+,Z(F>N9RE=J+.9LER*'H0&*_ZI@V-?K MVX2MZ.Q\<0N6F`H:;B9Y.$,.=45RN@%Z03Z)6DB3J^R!OL37&`Q?P+[_()NIU/GQ`=C9,-KJ[;F6DK+=)T2[@\ M.Y)9&TU:YXLL>]GCKPW;JNT!TB;@%-`%VV.C3:#277MLC^XT_?:RIP6[Q7:V M/V>#E@5\'2*%H7^W*+'VCR)CG`P7.-OO)=&T].>-M-6QANU1KB6P,B:.ML>] M%MCG#]%S!KSY-\9(=;:XK>3!>[&>VI]00<==4&Y[@Z"*7,L91%%(3:"[A4VT MG^WK.N"J=DP0-*$\T=LM4,*6H:-W1`^1$GMWTMDM\L*>X:GP?8'("XE+Q6ZA M%K:,F0++C^V)ILN!M&6RL#W3=(D/[,N9_=FE-0E5!1MQV]-/:\?.J4-+#B;_ M-(2$Y<.1-Z8.+B1,W(EZ[9-7-@P\3!&?2YK([+BXO&;%+,2BJ%8SFO`YV,71#,S_[:/DG*(_)33$?T?/E>IH M5&TDV&P\YK/[:'SUYCX[P03=\R5@%,@'E4(WHR8@#(W#A/AJXKPE0UE8J)9[ M:.0)KLK'>30@DE0'ZVN+J@MV:K.A@*O,U#0,-F[W4FA:7*]=VJ2IS8P56JO: M&ITV[CDJT5>*%EJEX=J],Z:JK5=MATX;UYQI*[19KQW:"/M]P-]FTC7K==JA MQ6K7D-P#41PIJ]M`2_03.\WTWMDRWU-.$RW2,=W^11=XF6FW6;D=>MU1-'.P MM_S\$][-J5PDLZ&>6HTUHW<\)RS^H#A$`_*J8NZ2@A`2O3+N/_,::I&^$I.EF9ZR!MJM7[G^;)MM]WVD MH.`[NL2.WG?_FF.*.*PS1>O^I9H82R>",!S%(+ET)R16$(%#>Z M;6)U+JA_R\1V%0AV5\NY8<,UF%]T:C9Y\E[G:>[Z^;W>*8WM82+[0ELU!]L> MCKB_T5QP>FI[S.*^@)89A&R/W]X7MEJ+FNW!WOL;R/JG#2GF=H8NF9^\Y",I M.]75"X^+-)BOZ%^,8,3@>@&:.%$(_X&`F#G"TPN>`_0,CV?T`N\`UH+3/+V8 M/(!1[<1C^^5&-0"XY8%B>QQ>U1AN>;S8?CU238-0YNAE>V1?+>N*PA/&UO`_ MR*FS,:C*.Q)DTSRJCFKT`B;?,4VI!D"-DSO;`R:K`7)'%_;=0BX/!603[ZK= MLN&V/XBUO.=.YOLW\$S02Y5EWY1J"*F)R]ANZ;7>[2`U--\JTXW8F16H&M#J ML:W;G@2ZL@&K[65H>^)H[80GY6X%W,&0>#L0%B+L6S)'9, MI#=GH_'=FF"/7)`+OH9];2(S:@DIY8M@B89LR>#7%L(+!!(()!!(()#M(I!E M5A@@F$`P@6`6$,P'/`GP&+O"XRP.EL'!Y([XV,6\QNZD$DC6P9(LO9&E(#-Z ME8$\`GFT;D$#\ECU%;*:,Q$01B",0!@+"..U@VGDR#+`S/4)FU,+>6+YU38? M'OGBFU\'V.Z[8+O`"H$5`BMLU\*>RPH+9FH@@T`&@0P6D,'TTQF-U^.L[Y$O MHDTO"0M9&HF]"GAM\JQZ5Y'E*^6NK<(I-E!.H)Q`.5NU-@+EK)AR[KSV`"D% M4@JDM("47CDTP,%$Q'=&'U.C=%,MC'S]4Y<'B@@4$2@B4,16K51`$:M.[Z!> M+X#\`?D#\E=`_E;WIJ1[+3B=WKYF6(:.?+7-K0(L$%@@L$!@@<`"JV6!^?,T M$$$@@D`$"XC@+X1XK]CW^X$WY"($$\S!BR_2`6HH670-\9(ORH:-`'T$^@CT M$>@CT,=JZ:/I7`Z$$@@E$,H"0KEQEZ"XPGWK%3 MU3``>5?)B8"\++!`8('``H$%M@LB,Q:HF`6![`'9`[)7&`PCKIM_=-[`XU$: M#).#CGRES:WR_GDK,$!@@,``@0&VBP'FS]-`!($(`A$L(())@JD[AX:+1^H$ MC$]`7`R;(V&`4^V/HY@,+SF!,6D!6".P1NO6-V"-%;-&HSD)2"202""1!23R M`4W$WWLT(U2X8@!Y!/)8!571&%8*_J)1$\@BD$7KUC$@BU7?$*@S!P%)!)+8 M?I+XJ2?D?'(8XO_S?U!+`P04````"``"AZ=`?YNHH?D&``"5-```$0`<`&%N M:6LM,C`Q,C`S,S$N>'-D550)``/D-JA/Y#:H3W5X"P`!!"4.```$.0$``.U; MVV[;.!!]+]!_X.JI"ZPL*[=MC+A%FDMA($T"Q^T6^U+0$FT3I4F5I!+[[W=( M2;9L*XID%=@M5B^-3,TYG.$9T2-Z>O9^,6?HD4A%!>\[?J?K(,(#$5(^[3N? M']SSAXO!P'G_[O6KL]]<%UU(@C4)T7B)/L2*^?KIYL';.ZUTMQI+1#809R3"''N5*8QZ0'`0B^5Z",+?'6.41BQU(ZI9_>GKJV;LYZUBY M4XRCE?T$J[&U3F_`-+[O=GWWT-]$Z65$5"',WBG&84XW73,#6,]`IHC$F@:J M$XBYP1YT#S>07'`>SXM7(M32,Y-Z8.2"%9$TR$-?QNU@C$VH5[#\HA][R,4UU/X2J%#"A7)D9]XV MPS9YK$AXQ]_9ZP"S(&86>`.?4W!J40:,)%$FG/K(M6?/X]+13*>?+=\#^&T3 M[FYR33GLAA2S>Z&L4Q<,*Y7FG1%P"(!O%0'E.AZ">"LBN+X0/"0<`C=72C`: MVF^<#YB9_1D]S`C1"KV).8Y#"G=^;Z7]6=+>8PDF,P(DF-76V:)?$/NHJ=CH MS8:3K?CUQ!]`;3 MH+="$S42JUUWO:ZW6,>2W$W63U%.X%JP@F#D35[`VR% M;")DMHJ71`621L;+@/3`3?*PF]!VUY(KS=3@3+9?(@ MS];F0I-<>*!3#K54@+D^#^S;*^73>]A5`PJ(6OI7I"K7_'1;\R$)S+Z_9@3Q M(;(8BK5DMQ\H%YAF\]<"&:]ZREA95 M+PN:SE&>)_YVGES]B)/S%[-;F'+^'M[GVBQIDB576'+8;]4]D5:H>OH_CRY7 M]F!'V90(`1.R5*VL360=\$?X(^1ROZGN3%R')E M=P[S#(FK@049FE;*9J6<^Y6]48GL61J_@Y))*3YKMM7[2H\I2H? M[!S"I91)A4[$%`*!_UNQB_C'==T,R0;:QKF?:R?J.HO.($2<=PS(P^/*6 M/"^2(B+2E,I>1IL1[*`W>P!M$FVM7^I5QC"39-)W3#*Z66_7-T!T%G.6F6BJ MS2P7:QYDB-0?"#/F>/_=R#=EK!`X``H"OUS1_")Q,SPFK&+(8%L0\HUA^$6B MW7[,*P0-D(*@\[\3%L5^YN7[$N'39M_B&80.FRCBA>V4S[3SHJ1C^$8$EJ@$ M8CZY&+!>Z7H>9+BZ'A3VR5:=.P.828\K35?:=?S< MM';*PC9GCS"M5ESNFJO^ZN^T%E=:A&V468E3L_S^21,7739,O(/L?*7ISP8G&$L.AG>CK&+\[\5VYB7/`5S^`U!+`0(>`Q0````(``*'IT`: M('`>5DP``&9\`P`1`!@```````$```"D@0````!A;FEK+3(P,3(P,S,Q+GAM M;%54!0`#Y#:H3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``*'IT`>[H76 MA`L``)B9```5`!@```````$```"D@:%,``!A;FEK+3(P,3(P,S,Q7V-A;"YX M;6Q55`4``^0VJ$]U>`L``00E#@``!#D!``!02P$"'@,4````"``"AZ=`7_Q@ M$W82```^7@$`%0`8```````!````I(%T6```86YI:RTR,#$R,#,S,5]D968N M>&UL550%``/D-JA/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@``H>G0$'1 M)%]D'@``B*`Q0````(``*'IT!E M@5]V?Q,``,>E`0`5`!@```````$```"D@>R)``!A;FEK+3(P,3(P,S,Q7W!R M92YX;6Q55`4``^0VJ$]U>`L``00E#@``!#D!``!02P$"'@,4````"``"AZ=` M?YNHH?D&``"5-```$0`8```````!````I(&ZG0``86YI:RTR,#$R,#,S,2YX M`L``00E#@``!#D!``!02P4&``````8`!@`:`@``_J0` #```` ` end XML 23 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party
3 Months Ended

Mar. 31, 2012

Related Party

13.          Related Party

In connection with our acquisition of Anika S.r.l. on December 30, 2009, Fidia Farmaceutici S.p.A. (“Fidia”) acquired ownership of 1,981,192 shares of the Company's common stock, of which 500,000 shares remain in escrow at March 31, 2012. As of March 31, 2012, Fidia owns approximately 14.4% of the outstanding shares of the Company.

As part of the acquisition, the Company, primarily through Anika S.r.l., entered into a series of operating agreements with Fidia as follows:

Agreement Type

Description

Term in Years

Lease

Rent of space in Abano Terme, Italy

Six

Finished goods supply

Manufacture and supply of goods

Three

Raw material supply

Hyaluronic acid powder

Five

Services

Finance, administrative, security

One to Six

Accounts receivable

Collection of trade receivables outstanding as of

Two

management

December 30, 2009.

Historically, Anika S.r.l. has relied on Fidia, its former parent company, for several functional activities. In connection with the purchase of Anika S.r.l., the Company has negotiated a lease for approximately 26,000 square feet of office, laboratory and warehouse space in Abano Terme, Italy, and a finished goods supply agreement. At March 31, 2012, Anika S.r.l. had a payable due to Fidia for past products and services of approximately $1.0 million.

X

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) (USD $)
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Product revenue $ 13,613,328 $ 11,060,159

Licensing, milestone and contract revenue 747,332 677,520

Total revenue 14,360,660 11,737,679

Operating expenses:

Cost of product revenue 6,413,481 5,604,562

Research & development 1,533,103 1,532,664

Selling, general & administrative 3,351,016 4,043,774

Total operating expenses 11,297,600 11,181,000

Income from operations 3,063,060 556,679

Interest income (expense), net (51,203) (40,921)

Income before income taxes 3,011,857 515,758

Provision for income taxes 1,099,738 191,346

Net income 1,912,119 324,412

Basic net income per share:

Net income $ 0.15 $ 0.03

Basic weighted average common shares outstanding 13,162,824 12,688,819

Diluted net income per share:

Net income $ 0.14 $ 0.02

Diluted weighted average common shares outstanding 14,089,946 13,744,710

Net income 1,912,119 324,412

Other comprehensive income

Foreign currency translation adjustment 756,461 1,749,662

Comprehensive income $ 2,668,580 $ 2,074,074

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 8, 9, 10, 11, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6508144

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 2

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 11, 12, 36

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph h

-Subparagraph 1(i)

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net amount of nonoperating interest income (expense).

+ References

No definition available.

+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 24

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 19, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 13, 20, 31

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 4

-Paragraph 5A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Inventories
3 Months Ended

Mar. 31, 2012

Inventories

7.             Inventories

Inventories consist of the following:

March 31,

December 31,

2012

2011

Raw materials
$ 5,035,600 $ 4,091,366

Work-in-process
2,000,603 1,503,565

Finished goods
2,044,120 1,707,552

Total
$ 9,080,323 $ 7,302,483

Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead.

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Earnings Per Share
3 Months Ended

Mar. 31, 2012

Earnings Per Share

6.             Earnings Per Share

The Company reports earnings per share in accordance with Accounting Standards Codification (“ASC”) 260, Earnings Per Share, which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding and the number of dilutive potential common share equivalents during the period. Under the treasury stock method, unexercised “in-the-money” stock options are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period.

Basic and diluted earnings per share for the three months ended March 31, 2012 and 2011 are as follows:

Three months ended March 31,

2012

2011

Shares used in the calculation of Basic earnings per share
13,162,824 12,688,819

Effect of dilutive securities:

Stock options, SARs, RSAs, and shares held in escrow
927,122 1,055,891

Diluted shares used in the calculation of earnings per share
14,089,946 13,744,710

In connection with the acquisition of Anika Therapeutics S.r.l. (“Anika S.r.l.”) on December 30, 2009, the Company issued 1,981,192 shares of its common stock of which 500,000 of these shares remain in escrow at March 31, 2012. These 500,000 shares are included in the diluted potential common shares but are excluded from the basic earnings per share calculation. See Note 10 for additional information relative to this item.

Equity awards of 380,551 and 979,438 shares were outstanding for the three months ended March 31, 2012 and 2011, respectively, but were not included in the computation of diluted earnings per share because the awards’ impact on earnings per share was anti-dilutive.

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Segment and Geographic Information
3 Months Ended

Mar. 31, 2012

Segment and Geographic Information

14.          Segment and Geographic Information

The Company has one reportable operating segment, the results of which are disclosed in the accompanying unaudited condensed consolidated financial statements.

Product revenue by product group is as follows:

Three Months Ended March 31,

2012

2011

Orthobiologics
$ 10,116,845 $ 8,036,298

Dermal
501,315 589,153

Ophthalmic
1,323,994 897,808

Surgical
983,628 1,113,728

Veterinary
687,546 423,172

$ 13,613,328 $ 11,060,159

Product revenue by geographic location in total and as a percentage of total product revenue, for the three months ended March 31, 2012 and 2011 are as follows:

Three Months Ended March 31,

2012

2011

Percentage of

Percentage of

Geographic Location:

Revenue

Revenue

Revenue

Revenue

United States
$ 10,390,045 76 % $ 8,343,114 76 %

Europe
2,155,729 16 % 2,033,198 18 %

Other
1,067,554 8 % 683,847 6 %

Total
$ 13,613,328 100 % $ 11,060,159 100 %

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
3 Months Ended

Mar. 31, 2012

Commitments and Contingencies

10.          Commitments and Contingencies

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any patent or intellectual property rights, trade secret or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligence or acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure. Based on the Company’s historical activity in combination with its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no accrued warranties and has no history of claims paid.

On July 7, 2010, Genzyme Corporation (“Genzyme”) filed a complaint against the Company in the United States District Court for the District of Massachusetts seeking unspecified damages and equitable relief. The Complaint alleges that the Company has infringed U.S. Patent No. 5,143,724 by manufacturing MONOVISC in the United States for sale outside the United States and will infringe U.S. Patent Nos. 5,143,724 and 5,399,351 if the Company begins manufacture and sale of MONOVISC in the United States. On August 30, 2010, the Company filed an answer denying liability. On April 26, 2011, Genzyme filed a motion to add its newly-issued U.S. Patent No. 7,931,030 to this litigation and also filed a separate new complaint in the District of Massachusetts alleging that the Company's manufacture and sale of MONOVISC in the United States will infringe that patent. On May 23, 2011, the Court entered orders permitting Genzyme to file its supplemental complaint adding its newly-issued U.S. Patent No. 7,931,030 to this litigation and requiring Genzyme to withdraw its separately filed complaint. On July 14, 2011, the Company filed an answer to the supplemental complaint, denying liability. The Company believes that neither MONOVISC, nor its manufacture, does or will infringe any valid and enforceable claim of the asserted patents. Management has assessed and determined that contingent losses related to this matter are not probable. Therefore, pursuant to ASC 450, Contingencies, an accrual has not been recorded for this loss contingency. Pursuant to the terms of the licensing and supply agreement entered into with Depuy Mitek, Inc. in December 2011, DePuy Mitek agreed to assume certain obligations of the Company related to this litigaton.

In 2011, Merogel Injectable was withdrawn from the market due to a labeling error on the product’s packaging. We are working with Medtronic to resolve a dispute related thereto. Medtronic has informed us that if we are unable to resolve this dispute, they will make claims against us. As this labeling error relates to conduct that initially occurred prior to our acquisition of Anika S.r.l. from Fidia Farmaceutici S.p.A., we have made claims against Fidia for indemnification for Anika’s losses as well as any potential claims that may be brought by Medtronic. Fidia has informed us that it does not believe that it has liability for this matter, and has made claims against us for refusing to release the Anika shares that were put into escrow in connection with the original transaction. Management has assessed and determined that contingent losses related to this matter are not probable. Therefore, pursuant to ASC 450, Contingencies, an accrual has not been recorded for this loss contingency.

We are also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, we do not expect the resolution of these other legal proceedings to have a material adverse effect on our financial position, results of operations or cash flow.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Intangible Assets and Goodwill
3 Months Ended

Mar. 31, 2012

Intangible Assets and Goodwill

8.             Intangible Assets and Goodwill

In connection with the acquisition of Anika S.r.l., the Company acquired various intangible assets and goodwill. The Company evaluated the various intangibles and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangibles. The in-process research and development intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition including write-off(s) for abandoned projects. Until such determination is made, they are not amortized.

The Company reviews its long-lived assets for impairment at least annually. Additionally, the Company will initiate a review for impairment if events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of the assets are no longer appropriate. Each impairment test will be based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Intangible assets as of March 31, 2012 and December 31, 2011 consist of the following:

March 31, 2012
December 31, 2011

Gross Value

Currency

Translation Adjustment

Accumulated Amortization

Net Book

Value

Net Book

Value

Useful Life

Developed technology
$ 16,700,000 $ (1,158,450 ) $ (2,275,506 ) $ 13,266,044 $ 13,228,351 15

In-process research & development
6,698,000 (464,629 ) - 6,233,371 5,955,066
Indefinite

Distributor relationships
4,700,000 (326,031 ) (1,968,286 ) 2,405,683 2,547,842 5

Patents
1,000,000 (69,368 ) (130,870 ) 799,762 790,555 16

Elevess trade name
1,000,000 - (404,587 ) 595,413 626,749 9

Total
$ 30,098,000 $ (2,018,478 ) $ (4,779,249 ) $ 23,300,273 $ 23,148,563

The aggregate amortization expense related to intangible assets was $516,278 and $537,040 for the three months ended March 31, 2012 and 2011, respectively.

Changes in the carrying value of goodwill for the three months ended March 31, 2012 were as follows:

Balance at December 31, 2011
$ 8,883,407

Effect of foreign currency adjustments
266,866

Balance at March 31, 2012
$ 9,150,273

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 43, 44, 45, 46, 47

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accrued Expenses
3 Months Ended

Mar. 31, 2012

Accrued Expenses

9.             Accrued Expenses

Accrued expenses consist of the following:

March 31,

December 31,

2012

2011

Payroll and benefits
$ 1,783,448 $ 2,366,412

Professional fees
483,488 793,430

Research grants
1,019,284 989,556

Other
1,011,167 1,172,196

Total
$ 4,297,387 $ 5,321,594

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Long-term Debt
3 Months Ended

Mar. 31, 2012

Long-term Debt

11.          Long-term Debt

On January 31, 2008, the Company entered into an unsecured Credit Agreement with Bank of America. As of March 31, 2012, the Company had an outstanding debt balance of $10,800,000, at an interest rate of 1.72%. The interest payable on our debt is determined, at the Company’s option, based on LIBOR plus 1.25%, or the lender’s prime rate.

ASC 825, Financial Instruments, requires disclosure about the fair value of financial instruments in interim as well as in annual financial statements. The carrying value of our debt instrument was $10,800,000 and $11,200,000 at March 31, 2012 and December 31, 2011, respectively, of which $1,600,000 was recorded as current at each date. The estimated fair value of our debt, which is a Level 2 instrument for fair value measurement purposes, approximated book value at March 31, 2012 and December 31, 2011, respectively.

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Cash flows from operating activities:

Net income $ 1,912,119 $ 324,412

Adjustments to reconcile net income to net cash (used in) provided by operating activities:

Depreciation and amortization 986,913 920,410

Stock-based compensation expense 320,510 300,275

Deferred income taxes (82,206) (111,293)

Provision for inventory 49,558 711,533

Tax benefit from exercise of stock options (394,076)

Changes in operating assets and liabilities:

Accounts receivable 358,471 2,753,690

Inventories (1,769,606) (374,014)

Prepaid expenses, other current and long-term assets (324,152) (580,852)

Long-term deposits and other 8,499 8,499

Accounts payable (476,940) (1,021,405)

Accrued expenses (1,341,407) (966,151)

Deferred revenue (716,667) (668,190)

Income taxes payable (215,156) 2,198

Other long-term liabilities (5,509) (13,165)

Net cash (used in) provided by operating activities (1,689,649) 1,285,947

Cash flows from investing activities:

Purchase of property and equipment, net (224,059) (76,570)

Net cash used in investing activities (224,059) (76,570)

Cash flows from financing activities:

Principal payments on debt (400,000) (400,000)

Proceeds from exercise of stock options 114,656 28,945

Tax benefit from exercise of stock options 394,076

Net cash provided by (used in) financing activities 108,732 (371,055)

Exchange rate impact on cash 30,932 38,556

(Decrease) increase in cash and cash equivalents (1,774,044) 876,878

Cash and cash equivalents at beginning of period 35,777,222 28,201,932

Cash and cash equivalents at end of period $ 34,003,178 $ 29,078,810

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 289

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 00-15

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4542-108314

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 4

-Section 7

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 86

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Reductions in the entity's income taxes that arise when compensation cost (from non-qualified stock options) recognized on the entity's tax return exceeds compensation cost from non-qualified stock options recognized on the income statement. This element increases net cash provided by operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A132

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11374-113907

+ Details

Name: us-gaap_TaxBenefitFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Equity Incentive Plan
3 Months Ended

Mar. 31, 2012

Equity Incentive Plan

5.             Equity Incentive Plan

The Company estimates the fair value of stock options and stock appreciation rights using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. The fair value of each stock option award during the three months ended March 31, 2012 and 2011 was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

Three Months Ended

March 31,

2012

2011

Risk free interest rate

0.64%

1.51%

Expected volatility

57.60%

57.60%

Expected lives (years)

4

4

Expected dividend yield

0.00%

0.00%

The Company recorded $320,510 and $300,275 of share-based compensation expense for the three months ended March 31, 2012 and 2011, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to the respective employees.

There were 119,000 stock options granted under the Second Amended and Restated 2003 Stock Option and Incentive Plan (the “Second Amended 2003 Plan”) during the three months ended March 31, 2012. There were 16,480 restricted stock units (“RSUs”) granted to members of the Company’s Board of Directors under the Second Amended 2003 Plan during the same period ended March 31, 2012. The stock options and RSUs granted to employees and directors become exercisable or vest ratably over four years from the date of grant.

As of March 31, 2012, there was approximately $2.8 million of total unrecognized compensation cost related to non-vested stock options, stock appreciation rights (“SARs”), and restricted stock awards (“RSAs”) granted under the Company’s incentive plans. This cost is expected to be recognized over a weighted-average period of 2.6 years.

The total intrinsic value of stock options and SARs exercised during the three month periods ended March 31, 2012 and 2011 was approximately $1,192,545 and $13,875, respectively. Cash received from the exercise of stock options during the three-month periods ended March 31, 2012 and 2011 was $114,656 and $28,945, respectively.

There were approximately 2.0 million options and SARs outstanding under the Company’s incentive plans at March 31, 2012 with a weighted-average exercise price of $7.71 per share, an aggregate intrinsic value of approximately $9.9 million, and a weighted-average remaining contractual term of 6.78 years.

None of the options or SARs outstanding at March 31, 2012 or 2011, respectively, had cash-settlement features.

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either authorized but unissued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. Awards contain service or performance conditions and generally become exercisable ratably over one to four years and have a ten year contractual term.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 7 106 1 false 0 0 false 3 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.anikatherapeutics.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.anikatherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets (unaudited) false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://www.anikatherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) Sheet http://www.anikatherapeutics.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.anikatherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (unaudited) false false R6.htm 107 - Disclosure - Nature of Business Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Nature of Business false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock Basis of Presentation false false R8.htm 109 - Disclosure - Recent Accounting Pronouncements Issued or Adopted Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Recent Accounting Pronouncements Issued or Adopted false false R9.htm 110 - Disclosure - Fair Value Measurements Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R10.htm 111 - Disclosure - Equity Incentive Plan Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Equity Incentive Plan false false R11.htm 112 - Disclosure - Earnings Per Share Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings Per Share false false R12.htm 113 - Disclosure - Inventories Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories false false R13.htm 114 - Disclosure - Intangible Assets and Goodwill Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Intangible Assets and Goodwill false false R14.htm 115 - Disclosure - Accrued Expenses Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R16.htm 117 - Disclosure - Long-term Debt Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-term Debt false false R17.htm 118 - Disclosure - Income Taxes Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R18.htm 119 - Disclosure - Related Party Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party false false R19.htm 120 - Disclosure - Segment and Geographic Information Sheet http://www.anikatherapeutics.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment and Geographic Information false false All Reports Book All Reports Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets (unaudited) Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) Process Flow-Through: 106 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) anik-20120331.xml anik-20120331.xsd anik-20120331_cal.xml anik-20120331_def.xml anik-20120331_lab.xml anik-20120331_pre.xml true true

Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Product revenue	$ 13,613,328	$ 11,060,159
Licensing, milestone and contract revenue	747,332	677,520
Total revenue	14,360,660	11,737,679
Operating expenses:
Cost of product revenue	6,413,481	5,604,562
Research & development	1,533,103	1,532,664
Selling, general & administrative	3,351,016	4,043,774
Total operating expenses	11,297,600	11,181,000
Income from operations	3,063,060	556,679
Interest income (expense), net	(51,203)	(40,921)
Income before income taxes	3,011,857	515,758
Provision for income taxes	1,099,738	191,346
Net income	1,912,119	324,412
Basic net income per share:
Net income	$ 0.15	$ 0.03
Basic weighted average common shares outstanding	13,162,824	12,688,819
Diluted net income per share:
Net income	$ 0.14	$ 0.02
Diluted weighted average common shares outstanding	14,089,946	13,744,710
Net income	1,912,119	324,412
Other comprehensive income
Foreign currency translation adjustment	756,461	1,749,662
Comprehensive income	$ 2,668,580	$ 2,074,074

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net income	$ 1,912,119	$ 324,412
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization	986,913	920,410
Stock-based compensation expense	320,510	300,275
Deferred income taxes	(82,206)	(111,293)
Provision for inventory	49,558	711,533
Tax benefit from exercise of stock options	(394,076)
Changes in operating assets and liabilities:
Accounts receivable	358,471	2,753,690
Inventories	(1,769,606)	(374,014)
Prepaid expenses, other current and long-term assets	(324,152)	(580,852)
Long-term deposits and other	8,499	8,499
Accounts payable	(476,940)	(1,021,405)
Accrued expenses	(1,341,407)	(966,151)
Deferred revenue	(716,667)	(668,190)
Income taxes payable	(215,156)	2,198
Other long-term liabilities	(5,509)	(13,165)
Net cash (used in) provided by operating activities	(1,689,649)	1,285,947
Cash flows from investing activities:
Purchase of property and equipment, net	(224,059)	(76,570)
Net cash used in investing activities	(224,059)	(76,570)
Cash flows from financing activities:
Principal payments on debt	(400,000)	(400,000)
Proceeds from exercise of stock options	114,656	28,945
Tax benefit from exercise of stock options	394,076
Net cash provided by (used in) financing activities	108,732	(371,055)
Exchange rate impact on cash	30,932	38,556
(Decrease) increase in cash and cash equivalents	(1,774,044)	876,878
Cash and cash equivalents at beginning of period	35,777,222	28,201,932
Cash and cash equivalents at end of period	$ 34,003,178	$ 29,078,810